<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD with MathML3 v1.1 20151215//EN" "JATS-journalpublishing1-mathml3.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink"
         xmlns:mml="http://www.w3.org/1998/Math/MathML"
         xmlns:ali="http://www.niso.org/schemas/ali/1.0/"
         xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
         dtd-version="1.1"
         xml:lang="sl"
         article-type="other">
   <front>
      <journal-meta>
         <journal-id journal-id-type="publisher-id">Zdrav Vestn</journal-id>
         <journal-id journal-id-type="nlm-ta">Zdrav Vestn</journal-id>
         <journal-id journal-id-type="doi">Zdrav Vestn</journal-id>
         <journal-title-group>
            <journal-title>Zdravniški vestnik</journal-title>
            <trans-title-group xml:lang="en">
               <trans-title>Slovenian Medical Journal</trans-title>
            </trans-title-group>
            <abbrev-journal-title>Zdrav Vestn</abbrev-journal-title>
         </journal-title-group>
         <issn publication-format="ppub" pub-type="ppub">1318-0347</issn>
         <issn publication-format="epub" pub-type="epub">1581-0224</issn>
         <issn-l>0350-0063</issn-l>
         <publisher>
            <publisher-name xml:lang="sl">Slovensko zdravniško društvo</publisher-name>
            <publisher-name xml:lang="en">Slovenian Medical Association</publisher-name>
            <publisher-loc xml:lang="sl">Ljubljana, Slovenia</publisher-loc>
         </publisher>
      </journal-meta>
      <article-meta>
         <article-id pub-id-type="doi">10.6016/ZdravVestn.2705</article-id>
         <article-id pub-id-type="publisher-id">2705</article-id>
         <article-categories>
            <subj-group subj-group-type="discipline" xml:lang="en">
               <subject>Medicine and health sciences</subject>
               <subj-group>
                  <subject>Metabolic and hormonal disorders</subject>
               </subj-group>
            </subj-group>
            <subj-group subj-group-type="discipline" xml:lang="sl">
               <subject>Medicina/Zdravstvo</subject>
               <subj-group>
                  <subject>Metabolne in hormonske motnje</subject>
               </subj-group>
            </subj-group>
            <subj-group subj-group-type="article-type" xml:lang="en">
               <subject>Professional article</subject>
            </subj-group>
            <subj-group subj-group-type="article-type" xml:lang="sl">
               <subject>Strokovni članek</subject>
            </subj-group>
            <subj-group subj-group-type="heading" xml:lang="sl">
               <subject>Metabolne in hormonske motnje</subject>
            </subj-group>
         </article-categories>
         <title-group>
            <article-title xml:lang="sl">Zaviralci SGLT-2: novost v zdravljenju sladkorne bolezni tipa 2</article-title>
            <trans-title-group>
               <trans-title xml:lang="en">SGLT-2 inhibitors: a novelty in the treatment of type 2 diabetes</trans-title>
            </trans-title-group>
            <alt-title alt-title-type="running-head" xml:lang="sl">Zaviralci SGLT-2</alt-title>
         </title-group>
         <contrib-group>
            <contrib contrib-type="author" xlink:type="simple">
               <name name-style="western">
                  <surname>Lunder</surname>
                  <given-names>Mojca</given-names>
               </name>
               <xref ref-type="aff" rid="aff1">1</xref>
            </contrib>
            <contrib contrib-type="author" xlink:type="simple">
               <name name-style="western">
                  <surname>Janić</surname>
                  <given-names>Miodrag</given-names>
               </name>
               <xref ref-type="aff" rid="aff2">2</xref>
            </contrib>
            <contrib contrib-type="author" xlink:type="simple">
               <name name-style="western">
                  <surname>Šabovič</surname>
                  <given-names>Mišo</given-names>
               </name>
               <xref ref-type="aff" rid="aff2">2</xref>
            </contrib>
            <contrib contrib-type="author" xlink:type="simple">
               <name name-style="western">
                  <surname>Janež</surname>
                  <given-names>Andrej</given-names>
               </name>
               <xref ref-type="aff" rid="aff1">1</xref>
            </contrib>
         </contrib-group>
         <aff-alternatives id="aff1">
            <aff xml:lang="sl">
               <label>1</label>
               <institution>Klinični oddelek za endokrinologijo, diabetes in presnovne bolezni, Interna klinika, Univerzitetni klinični center Ljubljana, Ljubljana, Slovenija</institution>
            </aff>
            <aff xml:lang="en">
               <label>1</label>
               <institution>Department of Endocrinology, Diabetes and Metabolic Diseases, Division of Internal Medicine, University Medical Centre Ljubljana, Ljubljana, Slovenia</institution>
            </aff>
         </aff-alternatives>
         <aff-alternatives id="aff2">
            <aff xml:lang="sl">
               <label>2</label>
               <institution>Klinični oddelek za žilne bolezni, Interna klinika, Univerzitetni klinični center Ljubljana, Ljubljana, Slovenija</institution>
            </aff>
            <aff xml:lang="en">
               <label>2</label>
               <institution>Department of Vascular Diseases, Division of Internal Medicine, University Medical Centre Ljubljana, Ljubljana, Slovenia</institution>
            </aff>
         </aff-alternatives>
         <author-notes>
            <fn fn-type="conflict" xml:lang="en">
               <p>The authors have declared that no competing interests exist.</p>
            </fn>
            <fn fn-type="conflict" xml:lang="sl">
               <p>Avtorji so izjavili, da ne obstajajo nobeni konkurenčni interesi.</p>
            </fn>
            <corresp id="corr">, e-mail: <email xlink:type="simple"/>
            </corresp>
         </author-notes>
         <pub-date pub-type="ppub">
            <month>10</month>
            <year>2018</year>
         </pub-date>
         <pub-date pub-type="epub">
            <month>10</month>
            <year>2018</year>
         </pub-date>
         <volume>87</volume>
         <issue>9–10</issue>
         <fpage>493</fpage>
         <lpage>505</lpage>
         <history>
            <date date-type="received">
               <day>23</day>
               <month>1</month>
               <year>2018</year>
            </date>
            <date date-type="accepted">
               <day>10</day>
               <month>5</month>
               <year>2018</year>
            </date>
         </history>
         <permissions>
            <copyright-statement xml:lang="en">Copyright © 2018, Slovenian Medical Association (SZD)</copyright-statement>
            <copyright-statement xml:lang="sl">© 2018, Slovensko zdravniško društvo (SZD)</copyright-statement>
            <copyright-year>2018</copyright-year>
            <copyright-holder xml:lang="en">Slovenian Medical Association (SZD)</copyright-holder>
            <copyright-holder xml:lang="sl">Slovensko zdravniško društvo (SZD)</copyright-holder>
            <license xlink:href="https://creativecommons.org/licenses/by-nc/4.0/"
                     xlink:type="simple"
                     xml:lang="en">
               <license-p>This is an open access article distributed under the terms of the
          <ext-link ext-link-type="uri"
                            xlink:href="https://creativecommons.org/licenses/by-nc/4.0/"
                            xlink:type="simple">Creative Commons Attribution-NonCommercial
            License</ext-link>, which permits unrestricted use, distribution, and
          reproduction in any medium, provided the original author and source are
          credited and only for non-commercial purposes. </license-p>
            </license>
            <license xlink:href="https://creativecommons.org/licenses/by-nc/4.0/"
                     xlink:type="simple"
                     xml:lang="sl">
               <license-p>To je članek z odprtim dostopom, ki ga lahko uporabite pod pogoji iz
          <ext-link ext-link-type="uri"
                            xlink:href="https://creativecommons.org/licenses/by-nc/4.0/"
                            xlink:type="simple">Creative Commons Priznanje avtorstva-Nekomercialno
            licence</ext-link>. ki dovoljuje distribucijo, predelavo ali
          prilagoditev, ter gradijo na njem, v nekomercialne namene, z navedbo avtorja
          in izvirnega dela.</license-p>
            </license>
         </permissions>
         <abstract xml:lang="sl">
            <title>Izvleček</title>
            <p>Zaviralci natrij-glukoznega prenašalnega sistema 2 (SGLT-2) so najnovejša skupina zdravil za zdravljenje sladkorne bolezni tipa 2, ki so v klinični uporabi zadnjih nekaj let. V proksimalnih tubulih ledvic zmanjšajo reabsorpcijo glukoze, ki se zato izloči z urinom. Zato se zniža koncentracija glukoze v krvi in nastopi ugodni vpliv na urejenost glikemije, obenem pa s tem ne povečajo tveganja za hipoglikemijo. Zaviralci SGLT-2 imajo tudi ugodne presnovne učinke, in sicer znižajo telesno maso, krvni tlak in koncentracijo sečne kisline v serumu. Upočasnijo tudi napredovanje začetne diabetične ledvične bolezni. Za nekatere predstavnike so tudi pokazali, da pomembno zmanjšujejo pojavnost srčno-žilnih dogodkov in zapletov, vendar mehanizem še ni v celoti raziskan in je predmet intenzivnega preučevanja. Redko povzročijo resne neželene učinke. V prispevku je opisan mehanizem delovanja zaviralcev SGLT-2, njihov vpliv na urejenost glikemije in drugo: presnovni učinki, vpliv na pojavnost srčno-žilnih bolezni in najpogostejši neželeni učinki ter možnosti predpisovanja zaviralcev SGLT-2 v Sloveniji.</p>
         </abstract>
         <trans-abstract xml:lang="en">
            <title>Abstract</title>
            <p>Sodium glucose co-transporter-2 (SGLT-2) inhibitors are the newest group of drugs for the treatment of diabetes mellitus type 2, which have been in clinical use for the last few years. They act in the proximal renal tubules by reducing the glucose reabsorption, the glucose then being excreted in the urine. Consequently, by decreasing blood glucose levels, they have a favourable effect on the glycaemia control and importantly do not increase the risk of hypoglycaemia. SGLT-2 inhibitors also possess favourable metabolic effects, especially on weight reduction, blood pressure reduction and serum uric acid level reduction. They also slow down the progression of the diabetic kidney disease. For some SGLT-2 inhibitors it was also shown that they exert beneficial effects on the cardiovascular system by reducing cardiovascular events and complications through yet unknown mechanisms, which are subject of intensive study. SGLT-2 inhibitors rarely cause serious side effects. The present manuscript describes the mechanism of action of SGLT-2 inhibitors, their effect on the glycaemia control, metabolic effects, effects on the incidence of cardiovascular disease, the most common side effects and prescribing restrictions for SGLT-2 inhibitors in Slovenia.</p>
         </trans-abstract>
         <kwd-group xml:lang="sl">
            <kwd>SGLT-2 zaviralci</kwd>
            <kwd>urejenost glikemije</kwd>
            <kwd>krvni tlak</kwd>
            <kwd>srčno-žilne bolezni</kwd>
            <kwd>neželeni učinki</kwd>
         </kwd-group>
         <kwd-group xml:lang="en">
            <kwd>SGLT-2 inhibitors</kwd>
            <kwd>glycaemia control</kwd>
            <kwd>blood pressure</kwd>
            <kwd>cardiovascular diseases</kwd>
            <kwd>undesired side effects</kwd>
         </kwd-group>
      </article-meta>
   </front>
   <body>
      <sec id="s1" sec-type="Uvod">
         <label>1</label>
         <title>Uvod</title>
         <p>Sladkorna bolezen je presnovna bolezen, za katero je značilna kronično povišana raven krvnega sladkorja. Njena pojavnost je v porastu in ima že pandemične razsežnosti. Ocenjujejo, da je imelo v letu 2017 sladkorno bolezen že 425 milijonov odraslih na svetu. Predvidevajo, da bo število bolnikov s sladkorno boleznijo do leta 2040 porastlo na okoli 642 milijonov. Do leta 2025 naj bi se tudi število smrti zaradi sladkorne bolezni in njenih zapletov povečalo za 50 % (<xref ref-type="bibr" rid="b1">1</xref>,<xref ref-type="bibr" rid="b2">2</xref>).</p>
         <p>Z obstoječimi zdravili urejenost glikemije še zdaleč ni optimalna, kar zahteva razvoj novih antihiperglikemičnih zdravil. Zaviralci natrij-glukoznega prenašalnega sistema 2 (<italic toggle="yes">angl.</italic> sodium-glucose transport system 2, SGLT-2) so najnovejša skupina zdravil, katerih uporabo za zdravljenje sladkorne bolezni tipa 2 sta Ameriška agencija za hrano in zdravila (<italic toggle="yes">angl.</italic> Food and Drug Administration, FDA) in Evropska agencija za zdravila (<italic toggle="yes">angl.</italic> European Medicines Agency, EMA) odobrila med letoma 2012 in 2014 (<xref ref-type="bibr" rid="b3">3</xref>).</p>
         <p>Prvi zaviralec SGLT-2 je bil florizin (<italic toggle="yes">angl.</italic> phlorisin), ki so ga osamili iz lubja jablan. Molekulo poznajo že več kot 200 let. Deluje neselektivno, saj zavira tako prenašalce SGLT-2 kot tudi SGLT-1. Pri živalih s sladkorno boleznijo je florizin uspešno normaliziral glikemijo in zmanjšal insulinsko rezistenco. Ni pa se izkazal kot ugoden za klinično zdravljenje, saj se slabo absorbira po peroralnem zaužitju, poleg tega pa zaradi zavore SGLT-1 povzroča driske in slabost, njegov presnovni produkt floretin pa zavira glukozni prenašalec 1 (<italic toggle="yes">angl.</italic> glucose transporter type 1, GLUT-1), ki se nahaja na eritrocitih in v krvno-možganski pregradi. Ne glede na to, pa je molekula florizina služila kot osnova za sintezo več selektivnih zaviralcev SGLT-2, kot so npr. empagliflozin, dapagliflozin, kanagliflozin in drugi (<xref ref-type="bibr" rid="b1">1</xref>).</p>
      </sec>
      <sec id="s2" sec-type="Mehanizem delovanja">
         <label>2</label>
         <title>Mehanizem delovanja</title>
         <p>Glukoza se v glomerulu prosto filtrira. Dnevno se pri posameznikih brez sladkorne bolezni filtrira približno 180 g glukoze, ki se nato skoraj v celoti reabsorbira v proksimalnem tubulu. Na ta način ledvice preprečujejo izgubo glukoze (<xref ref-type="bibr" rid="b1">1</xref>,<xref ref-type="bibr" rid="b4">4</xref>). Ko je presežen prag reabsorpcijske sposobnosti ledvic za glukozo, se pri zdravih pozameznikih prične izločanje glukoze z urinom (glukozurija). To se običajno zgodi, ko koncentracija glukoze v plazmi poraste nad 11 mmol/l (<xref ref-type="bibr" rid="b5">5</xref>). Na ta način ledvice delujejo zaščitno, saj preprečijo nadaljnji porast plazemske koncentracije glukoze in njene škodljive učinke (<xref ref-type="bibr" rid="b6">6</xref>).</p>
         <p>V proksimalnem tubulu se glukoza lahko reabsorbira pasivno preko prenašalcev GLUT in z aktivnim prenosom preko prenašalcev SGLT (<xref ref-type="bibr" rid="b4">4</xref>,<xref ref-type="bibr" rid="b6">6</xref>). Slednji opravijo privzem glukoze v celice, za kar uporabijo gradient natrija, ki se ustvari s pomočjo Na-K ATP-azne črpalke na bazolateralni strani celic (<xref ref-type="bibr" rid="b1">1</xref>). Poznamo dva tipa prenašalcev SGLT, in sicer SGLT-1 in SGLT-2. Prenašalci SGLT-1 se nahajajo predvsem v tankem črevesju, ledvicah, srcu in skeletnih mišicah, kjer skrbijo za aktivno absorpcijo glukoze v omenjena tkiva. SGLT-2 pa se nahajajo skoraj izključno v ledvicah, in sicer v proksimalnih tubulih. Tam omogočajo reabsorpcijo 80–90 % filtrirane glukoze, SGLT-1 pa je odgovoren za manj kot 10 % njene reabsorpcije (<xref ref-type="bibr" rid="b4">4</xref>-<xref ref-type="bibr" rid="b7">7</xref>). Pokazali so, da se število prenašalcev SGLT-2 pri bolnikih s sladkorno boleznijo presenetljivo poveča (<xref ref-type="bibr" rid="b1">1</xref>). Njihovo povečano izražanje ob porastu plazemske koncentracije glukoze omogoča zvišanje praga za glukozurijo, poveča se sposobnost reabsorpcije glukoze v proksimalnih tubulih, s čimer se koncentracija glukoze v plazmi še dodatno poviša (<xref ref-type="bibr" rid="b5">5</xref>).</p>
         <p>Zaviralci SGLT-2 delujejo tako, da zavirajo delovanje prenašalcev SGLT-2 v proksimalnih tubulih in s tem preprečijo reabsorpcijo glukoze. Zato se poveča glukozurija, kar zniža plazemsko koncentracijo glukoze in privede do ureditve glikemije (<xref ref-type="bibr" rid="b8">8</xref>). Pod vplivom zaviralcev SGLT-2 se dnevno izloči 20–100 gramov glukoze, kar predstavlja izgubo od 90–450 kcal dnevno (<xref ref-type="bibr" rid="b4">4</xref>). Delovanje zaviralcev SGLT-2 je odvisno od koncentracije glukoze v plazmi, saj se njihov učinek zmanjša ob nižjih vrednostih glukoze. Pri osebi brez sladkorne bolezni tako zaviralci SGLT-2 ne povzročijo enakega znižanja glukoze kot pri bolnikih s sladkorno boleznijo. Zaviralci SGLT-2 delujejo neodvisno od delovanja na izločanje insulina, zato ne povzročijo izčrpanja ß-celic trebušne slinavke in ne povečajo tveganja za hipoglikemijo (<xref ref-type="bibr" rid="b6">6</xref>). Mehanizem delovanja zaviralcev SGLT-2 je prikazan na <xref ref-type="fig" rid="fig1">Sliki 1</xref>.</p>
         <fig position="anchor" id="fig1" orientation="portrait">
            <label>Slika 1:</label>
            <caption>
               <p> Shematski prikaz delovanja zaviralcev SGLT-2 v ledvicah na ravni glomerula in proksimalnega tubula. Povzeto po Kalra S et al (<xref ref-type="bibr" rid="b5">5</xref>).</p>
            </caption>
            <p>
               <graphic xlink:href="2705-web-resources/image/zdravvestn-2705-sl-01.jpg"
                        position="float"
                        orientation="portrait"/>
            </p>
         </fig>
      </sec>
      <sec id="s3" sec-type="Osnovno antihiperglikemično delovanje">
         <label>3</label>
         <title>Osnovno antihiperglikemično delovanje</title>
         <p>V številnih raziskavah so pokazali, da zdravljenje z zaviralci SGLT-2 zniža HbA1c. Znižanje je bilo odvisno od izhodiščne vrednosti, in sicer je prišlo do znižanja HbA1c za 0,51–1,45 % ob izhodiščnem HbA1c med 7 in 9,1 % (<xref ref-type="bibr" rid="b1">1</xref>). V povprečju je ob zdravljenju z zaviralci SGLT-2 prišlo do znižanja HbA1c za 0,69 % v primerjavi s placebom (<xref ref-type="bibr" rid="b3">3</xref>). V raziskavi Empagliflozin Cardiovascular Outcomes and Mortality in Type 2 Diabetes trial (EMPA-REG OUCOME) so ugotovili, da empagliflozin v odmerku 10 mg dnevno zniža HbA1c za 0,54 %, v odmerku 25 mg dnevno pa za 0,6 % (<xref ref-type="bibr" rid="b9">9</xref>). Zdravljenje z zaviralci SGLT-2 zniža koncentracijo glukoze na tešče v povprečju za 0,9 mmol/l v primerjavi s placebom (<xref ref-type="bibr" rid="b3">3</xref>).</p>
         <p>Pojavnost hipoglikemij ob zdravljenju z zaviralci SGLT-2 ni bila večja v primerjavi s placebom. Najverjetneje je razlog je v tem, da delujejo popolnoma neodvisno od insulina. Poleg tega se učinek zaviralcev SGLT-2 ob znižanju koncentracije glukoze v plazmi zmanjša, zato se tudi na ta način prepreči nastanek hipoglikemije (<xref ref-type="bibr" rid="b5">5</xref>). Večjo pojavnost hipoglikemij so beležili le v primeru, ko so bolniki poleg zaviralca SGLT-2 prejemali druga antihiperglikemična zdravila, ki lahko povzročajo hipoglikemijo, kot so npr. sulfonilsečnine ali insulin (<xref ref-type="bibr" rid="b6">6</xref>). Zaviralci SGLT-2 so povzročili statistično značilno manj blagih hipoglikemij v primerjavi s sulfonilsečninami, pri katerih je bila pojavnost blagih hipoglikemij za približno 30 % večja kot pri placebu (<xref ref-type="bibr" rid="b10">10</xref>). Metaanaliza raziskav je pokazala, da je ob zdravljenju z dapagliflozinom in empagliflozinom verjetnost blage hipoglikemije nizka in primerljiva s placebom (<xref ref-type="bibr" rid="b3">3</xref>). Na <xref ref-type="fig" rid="fig2">Sliki 2</xref> je prikazan povzetek osnovnih učinkov zaviralcev SGLT-2 ter njihovih ugodnih in neželenih učinkov (opisani v nadaljnjem besedilu).</p>
         <fig position="anchor" id="fig2" orientation="portrait">
            <label>Slika 2:</label>
            <caption>
               <p> Pregledni prikaz osnovnih učinkov, dodatnih ugodnih učinkov in neželenih učinkov zaviralcev SGLT-2. HDL – lipoprotein z visoko gostoto (<italic toggle="yes">angl.</italic> high density lipoprotein), TG – trigliceridi, HbA1c – glikirani hemoglobin, LDL – lipoprotein z nizko gostoto (<italic toggle="yes">angl.</italic> low density lipoprotein).</p>
            </caption>
            <p>
               <graphic xlink:href="2705-web-resources/image/zdravvestn-2705-sl-02.png"
                        position="float"
                        orientation="portrait"/>
            </p>
         </fig>
      </sec>
      <sec id="s4" sec-type="Ugodni presnovni učinki">
         <label>4</label>
         <title>Ugodni presnovni učinki</title>
         <sec id="s4.1" sec-type="Znižanje telesne mase">
            <label>4.1</label>
            <title>Znižanje telesne mase</title>
            <p>Ob zdravljenju z zaviralci SGLT-2 pride do znižanja telesne mase za 1–5 kg, kar je običajno 2–5 % telesne mase. Večje znižanje so beležili pri bolnikih z dalj časa trajajočo sladkorno boleznijo in z višjo izhodiščno telesno maso (<xref ref-type="bibr" rid="b6">6</xref>). V raziskavi Lioudaki in sodelavcev so ugotovili, da je učinek zaviralcev SGLT-2 na znižanje telesne mase odvisen od odmerka zdravila, in sicer so pri nižjih odmerkih zaviralcev SGLT-2 beležili upad telesne mase za 1,61 kg, pri višjih odmerkih pa do 2,66 kg; pomemben podatek je, da so ob tem beležili tudi zmanjšanje obsega pasu (<xref ref-type="bibr" rid="b7">7</xref>). V drugi metaanalizi raziskav so ugotovili, da zaviralci SGLT-2 povzročijo pomembno znižanje telesne mase, in sicer dapagliflozin za 1,3–2,24 kg in empagliflozin za 1,84–1,93 kg. Statistično značilno razliko v znižanju telesne mase ob višanju odmerka zaviralca SGLT-2 so ugotovili pri zdravljenju z dapagliflozinom, pri zdravljenju z empagliflozinom pa te povezave niso potrdili (<xref ref-type="bibr" rid="b11">11</xref>). V primeru, ko so zaviralce SGLT-2 dodatno uvedli ob zdravljenju z insulinom, so s tem preprečili porast telesne mase zaradi samega zdravljenja z insulinom (<xref ref-type="bibr" rid="b6">6</xref>).</p>
            <p>Pri bolnikih, zdravljenih z zaviralci SGLT-2, so ugotovili hitro izgubo telesne mase v prvih 12–26 tednih zdravljenja, temu pa je sledilo obdobje, ko se je telesna masa v naslednjih 26 tednih ustalila ali le minimalno upadla. Izgubo telesne mase v začetnem obdobju povezujejo z izgubo tekočine zaradi osmozne diureze, kasnejšo pa z izgubo maščobnega tkiva. Glede na meritve z dvoenergijsko rentgensko absorpciometrijo (<italic toggle="yes">angl.</italic>
               <italic toggle="yes"> </italic>dual energy X-ray absorptiometry, DEXA) so ugotovili, da je 30 % izgubljene telesne mase na račun izgube telesne vode zaradi osmozne diureze, 70 % pa na račun izgube maščobnega tkiva (največ visceralnega, manj pa podkožnega maščevja) (<xref ref-type="bibr" rid="b1">1</xref>). Vzrok za izgubo maščobnega tkiva je najverjetneje v tem, da zdravljenje z zaviralci SGLT-2 preusmeri substrate za presnovo z ogljikovih hidratov na lipide, saj pride do povečanega izločanja glukoze iz telesa in s tem njenega sorazmernega pomanjkanja (<xref ref-type="bibr" rid="b1">1</xref>). Vsekakor pa vpliv zaviralcev SGLT-2 na znižanje telesne mase še ni popolnoma raziskan. Če upoštevamo, da se zaradi njihovega delovanja dnevno z urinom izloči do 100 g glukoze, bi samo na tej osnovi pričakovali večjo izgubo telesne mase (<xref ref-type="bibr" rid="b11">11</xref>).</p>
         </sec>
         <sec id="s4.2" sec-type="Znižanje koncentracije sečne kisline">
            <label>4.2</label>
            <title>Znižanje koncentracije sečne kisline</title>
            <p>Serumska vrednost sečne kisline oz. urata je pogosteje zvišana pri bolnikih s sladkorno boleznijo tipa 2 in je povezana z nastankom njenih kroničnih zapletov (<xref ref-type="bibr" rid="b6">6</xref>,<xref ref-type="bibr" rid="b12">12</xref>). Zaviralci SGLT-2 znižajo koncentracijo sečne kisline za 10–13 %; znižanje je večje pri posameznikih z višjimi izhodiščnimi vrednostmi (<xref ref-type="bibr" rid="b7">7</xref>). Pri zdravljenju s kanagliflozinom je prišlo do normalizacije vrednosti sečne kisline v serumu pri 20–30 % bolnikov s povišanimi vrednostmi. Dapagliflozin je tudi znižal koncentracijo sečne kisline. Učinek je izzvenel po ukinitvi zdravila. Empagliflozin je prav tako znižal koncentracijo sečne kisline (<xref ref-type="bibr" rid="b12">12</xref>). Najverjetneješi mehanizem je povečanje izločanja glukoze z urinom, saj ob tem pride do večje izmenjave sečne kisline na apikalni membrani tubulnih celic in povečanega izločanja sečne kisline iz krvi v urin. Slednje najverjetneje nastane zaradi vpliva na transportni sistem za sečno kislino v ledvičnih tubulih, npr. GLUT-9 (<xref ref-type="bibr" rid="b12">12</xref>).</p>
         </sec>
         <sec id="s4.3" sec-type="Učinki na presnovo maščob">
            <label>4.3</label>
            <title>Učinki na presnovo maščob</title>
            <p>Bolniki s sladkorno boleznijo tipa 2 imajo običajno profil krvnih maščob, za katerega so značilni hipertrigliceridemija, nizka koncentracija lipoproteinov z visoko gostoto (<italic toggle="yes">angl.</italic> high density lipoprotein, HDL) in presežek majhnih, gostih lipoproteinov nizke gostote (<italic toggle="yes">angl.</italic> low density lipoprotein, LDL). Zaviralci SGLT-2 nekoliko znižajo koncentracijo trigliceridov in povišajo koncentracijo HDL. Mehanizma teh učinkov sta verjetno preko znižanja telesne mase in znižanja glikemije, kar zmanjša tvorbo lipoproteinov z zelo nizko gostoto (<italic toggle="yes">angl.</italic> very low desnity lipoprotein, VLDL) v jetrih. Zato se zniža plazmenska koncentracija trigliceridov (<xref ref-type="bibr" rid="b7">7</xref>). V primerjavi s placebom zaviralci SGLT-2 povišajo koncentracijo HDL za 0,05 mmol/l, medtem ko je pričakovani upad koncentracije trigliceridov 0,09 mmol/l (<xref ref-type="bibr" rid="b3">3</xref>). Zaviralci SGLT-2 sicer lahko povišajo tudi koncentracijo LDL, kar zaradi možnega neugodnega delovanja na srčno-žilni sistem opisujemo med neželenimi učinki.</p>
         </sec>
         <sec id="s4.4" sec-type="Učinek na delovanje jeter">
            <label>4.4</label>
            <title>Učinek na delovanje jeter</title>
            <p>Zaviralci SGLT-2 v primerjavi s placebom znižajo raven alanin-aminofransferaze (ALT) za 2,8 IU/l. Ta učinek je ugoden pri nealkoholni zamaščenosti jeter, vendar ni jasno, ali je znižanje ALT posledica znižanja telesne mase zaradi delovanja zaviralcev SGLT-2 ali pa posledica njihovega neposrednega delovanja na jetra (<xref ref-type="bibr" rid="b3">3</xref>).</p>
         </sec>
      </sec>
      <sec id="s5" sec-type="Ugodni nepresnovni učinki">
         <label>5</label>
         <title>Ugodni nepresnovni učinki</title>
         <sec id="s5.1" sec-type="Znižanje krvnega tlaka">
            <label>5.1</label>
            <title>Znižanje krvnega tlaka</title>
            <p>Ugodne učinke zaviralcev SGLT-2 na znižanje krvnega tlaka so dokazali v več manjših in večjih raziskavah, pri katerih so beležili statistično značilno znižanje tako sistolnega kot diastolnega krvnega tlaka. Trend znižanja je večji pri sistolnem tlaku, učinek je odvisen od učinkovine in odmerka zaviralca SGLT-2. Učinki na krvni tlak so bili neodvisni od urejenosti glikemije in stopnje znižanja telesne mase (učinki, vidni kmalu po začetku zdravljenja z zaviralci SGLT-2), do večjega znižanja krvnega tlaka je prišlo pri bolnikih, ki so imeli višji izhodiščni sistolni tlak (<xref ref-type="bibr" rid="b6">6</xref>,<xref ref-type="bibr" rid="b7">7</xref>). V metaanalizi Shyangdana in sodelavcev so pokazali, da zdravljenje z zaviralci SGLT-2 v monoterapiji ali v kombinaciji z metforminom vodi v znižanje krvnega tlaka v primerjavi s placebom, in sicer do –2,6 mmHg pri zdravljenju z empagliflozinom 10 mg dnevno, in do –6 mmHg pri zdravljenju s kanagliflozinom 300 mg dnevno. V isti raziskavi so pokazali, da je povprečno znižanje sistolnega tlaka pri zdravljenju z zaviralci SGLT-2 za –3,77 mmHg in diastolnega tlaka za –1,75 mmHg. Pomembno je poudariti, da učinek zaviralcev SGLT-2 na znižanje krvnega tlaka ni bil povezan s porastom srčne frekvence (<xref ref-type="bibr" rid="b13">13</xref>). Največje znižanje krvnega tlaka je bilo ugotovljeno pri bolnikih, zdravljenih s kanagliflozinom (<xref ref-type="bibr" rid="b3">3</xref>).</p>
            <p>Ključna mehanizma, preko katerih zaviralci SGLT-2 povzročijo znižanje krvnega tlaka, sta najverjetneje osmozna diureza in povečano izločanje natrija z urinom (zmanjšanje količine natrija v telesu). Povečanje dotoka natrija v <italic toggle="yes">maculo denso</italic> ledvic, ob zavori SGLT-2, zmanjša izločanje renina in dolgoročno zavira sistem renin-angiotenzin-aldosteron, kar ugodno vpliva na krvni tlak. V prid tej teoriji govori tudi odsotnost porasta srčne frekvence (<xref ref-type="bibr" rid="b7">7</xref>). Dodatno lahko na znižanje krvnega tlaka vpliva tudi zmanjšanje arterijske togosti, kar so pokazali pri mladih bolnikih s sladkorno boleznijo tipa 1 (<xref ref-type="bibr" rid="b14">14</xref>).</p>
         </sec>
         <sec id="s5.2" sec-type="Zaščitno delovanje na ledvice">
            <label>5.2</label>
            <title>Zaščitno delovanje na ledvice</title>
            <p>Zaviralci SGLT-2 delujejo zaščitno na ledvice, in sicer preko izboljšanja urejenosti glikemije, preko znižanja krvnega tlaka in verjetno tudi preko neposrednega učinka na ledvice (zmanjšanja glomerulne hiperfiltracije, vnetja in fibroze). Z napredovanjem diabetične ledvične bolezni sčasoma prihaja do upada hitrosti glomerulne filtracije, s čimer se zmanjšuje tudi učinkovitost zaviralcev SGLT-2, saj se jih manj filtrira na mesto delovanja. Pri oGF &lt; 45 ml/min/1,73 m<sup>2</sup> izzveni njihov učinek na HbA1c, ne pa tudi ostali nepresnovni učinki (<xref ref-type="bibr" rid="b15">15</xref>).</p>
            <p>Diabetična ledvična bolezen nastane kot posledica več dejavnikov. Dva pomembna mehanizma vodita v glomerulno hiperfiltracijo, in sicer gre za okvarjeno nevrohumoralno aktivacijo (hemodinamski učinek) in tubulne dejavnike. Pri prvem gre za zmanjšanje tonusa aferentne arteriole v primerjavi z eferentno in porast znotrajglomerulnega tlaka, ki vodi v glomerulno hiperfiltracijo. Opisano je posledica povečane aktivnosti angiotenzina II, ki ima afiniteto za konstrikcijo eferentne arteriole. Drugi mehanizem se nanaša na povečano glukozno breme v proksimalnem tubulu in s tem čezmerno aktivnost SGLT-2 in SGLT-1 ter povečano tubulno reabsorpcijo glukoze in natrija v proksimalnih tubulih ter posledično aktiviranje tubulno-glomerulne povratne zanke, saj se zmanjša dotok natrija v <italic toggle="yes">maculo denso</italic> v distalnem delu nefrona. Slednje povzroči vazodilatacijo aferentne arteriole in povečano glomerulno filtracijo oz. hiperfiltracijo. Hiperfiltraciji sledi progresivno zmanjšanje hitrosti glomerulne filtracije, saj hiperfiltracija v zgodnjem obdobju povzroča sklerozo glomerulov, kompenzacijsko povečanje filtracije v preostalih zdravih glomerulih pa vodi v nadaljnjo sklerozo tudi teh (<xref ref-type="bibr" rid="b1">1</xref>,<xref ref-type="bibr" rid="b6">6</xref>,<xref ref-type="bibr" rid="b15">15</xref>).</p>
            <p>Zaviralci SGLT-2 povečajo dotok filtriranega bremena v distalni del nefrona, predvsem natrija, ki preko <italic toggle="yes">macule dense</italic> spodbudi lokalno izločanje adenozina in s tem vazokonstrikcijo aferentne arteriole. Zato se zmanjša znotrajglomerulni tlak in hitrost glomerulne filtracije, kar deluje zaščitno na glomerul (<xref ref-type="bibr" rid="b15">15</xref>,<xref ref-type="bibr" rid="b16">16</xref>). Za empagliflozin so pokazali, da zmanjša vnetje in stopnjo fibroze v ledvicah, ki nastajajo pod vplivom hiperglikemije, in tako omeji z glukozo povzročeno okvaro proksimalnih tubulov. Dodatno so pokazali, da je po 24 tednih zdravljenja znižal razmerje albumin:kreatinin v primerjavi s placebom pri bolnikih s sladkorno boleznijo in albuminurijo (za 41 %) (<xref ref-type="bibr" rid="b7">7</xref>). Glede na opisane mehanizme se za preprečevanje napredovanja diabetične nefropatije kaže kot najboljše zdravljenje kombinacija zaviralcev SGLT-2 in zaviralcev angiotenzinske konvertaze, saj je bolj učinkovita od posameznih zdravil (<xref ref-type="bibr" rid="b1">1</xref>).</p>
         </sec>
         <sec id="s5.3" sec-type="Ugodno delovanje na srčno-žilni sistem">
            <label>5.3</label>
            <title>Ugodno delovanje na srčno-žilni sistem</title>
            <p>Od leta 2008 FDA zahteva raziskave srčno-žilne varnosti pri zdravilih za zdravljenje sladkorne bolezni. Za zaviralce SGLT-2 imamo do izdaje tega članka na voljo rezultate dveh tovrstnih raziskav, in sicer že omenjeno EMPA-REG OUTCOME, ki je preučevala srčno-žilno varnost empagliflozina, ter Canagliflozin Cardiovascular Assesment Study (CANVAS), ki je preučevala varnost kanagliflozina; obe pri bolnikih s sladkorno boleznijo tipa 2. Raziskavi sta bili različno zasnovani, saj je EMPA-REG vključevala 99,5 % bolnikov, ki so predhodno že imeli srčno-žilni dogodek, medtem ko so v CANVAS vključili 67 % takih bolnikov. Primarni cilj obeh raziskav je bil ugotoviti učinek posameznih zaviralcev SGLT-2 na tri velike srčno-žilne dogodke (<italic toggle="yes">angl.</italic> major adverse cardiovascular events, MACE), ki so zajemali srčno-žilno smrt, neusodni miokardni infarkt in neusodno možgansko kap. V obeh raziskavah so pokazali znižanje MACE za 14 % glede na placebo in s tem večji pomen teh zdravil. Po drugi strani pa se je med posameznimi elementi MACE pokazala razlika med preučevanima zdraviloma. V EMPA-REG so pokazali zmanjšanje umrljivosti zaradi srčno-žilnih dogodkov v obdobju spremljanja (3,1 leto) za 38 %, medtem ko je bil v raziskavi CANVAS upad umrljivosti zaradi srčno-žilnih dogodkov v opazovalnem obdobju (6,0 let) le 13 %. Vzrokov za ugotovljene razlike je verjetno več, in sicer: različne značilnosti vključenih bolnikov (delež bolnikov z znano srčno-žilno boleznijo je bil različen), učinek drugih predpisanih zdravil z ugodnim delovanjem na srčno-žilni sistem, selektivnosti zaviralcev SGLT-2 za SGLT-2/SGLT-1 (&gt; 2500-krat za empagliflozin, &gt; 250-krat kanagliflozin) in statistične analize. Tudi čas do razklenitve preživetvenih krivulj v obeh raziskavah je bil različen. V EMPA-REG so omenjeni učinek opazili zgodaj, in sicer že po treh mesecih, kar pripisujejo hemodinamskim učinkom, hipotezi spremembe goriv za delovanje srčne mišice, izboljšanega učinka na presnovo maščob in izboljšanju delovanja endotela. Po drugi strani so v raziskavi CANVAS ta učinek zabeležili šele po enem letu, kar pripisujejo ugodnemu učinku kanagliflozina na zaviranje ateroskleroze (<xref ref-type="bibr" rid="b1">1</xref>,<xref ref-type="bibr" rid="b7">7</xref>,<xref ref-type="bibr" rid="b17">17</xref>-<xref ref-type="bibr" rid="b19">19</xref>).</p>
            <p>Pomembno je poudariti, da so v obeh opisanih raziskavah v skupinah zdravljenih z zaviralcem SGLT-2 beležili tudi pomembno manj hospitalizacij zaradi srčnega popuščanja, in sicer v raziskavi EMPA-REG za 35 % in v raziskavi CANVAS za 33 % v primerjavi s placebom (<xref ref-type="bibr" rid="b17">17</xref>-<xref ref-type="bibr" rid="b19">19</xref>). Opisanega ugodnega učinka se ne da pojasniti le s stopnjo vpliva na glikemijo, zato se sklepa, da gre za od glikemije neodvisen učinek, ki pa do sedaj še ni bil dokončno raziskan. V dosedanjih raziskavah so ugotovili, da zaviralci SGLT-2 zmanjšajo prostornino plazme in izboljšajo natriurezo ter odgovor na diuretično zdravljenje. Poleg tega tudi usmerijo miokard v energetsko bolj ugodno stanje (poraba ketonskih teles je v primerjavi s porabo glukoze namreč povezana z manjšo porabo kisika v miokardu za doseganje enakega dela). Zanimiv in verjetno pomemben mehanizem varovalnih učinkov na srčno-žilni sistem je tudi porast koncentracije serumskega magnezija. Znano je namreč, da magnezij varuje miokard pred pomembnimi motnjami srčnega ritma (<xref ref-type="bibr" rid="b20">20</xref>). Zaradi ugodnih učinkov na ledvice zaviralci SGLT-2 zmanjšujejo stopnjo ledvične okvare tudi pri bolnikih s srčnim popuščanjem. K vsemu naštetemu prispeva tudi ugoden učinek na endotelno funkcijo. Vse opisano kaže tudi na morebitno učinkovitost pri bolnikih s srčnim popuščanjem z ohranjenim iztisnim deležem, pri katerih do sedaj ni bilo na voljo zadovoljivih terapevtskih možnosti (<xref ref-type="bibr" rid="b8">8</xref>,<xref ref-type="bibr" rid="b21">21</xref>).</p>
            <p>Mehanizmi ugodnih učinkov zaviralcev SGLT-2 na srčno-žilni sistem še niso povsem raziskani. Verjetno gre za posredovanje preko znižanja arterijskega tlaka in znižanja togosti arterij, oba pa povzročata znižanje poobremenitve srca, kar povzroča zmanjšanje energetske porabe kiska v miokardu in povzroči izboljšanje srčne funkcije. Dodatno verjetno delujejo tudi preko znižanja telesne mase, nimajo spodbujevalnega učinka na simpatično živčevje, povečajo izločanje natrija iz telesa, zmanjšajo oksidativni stres, povečajo izločanje glukagona in verjetno ugodno delujejo tudi preko drugih, še nepoznanih mehanizmov (<xref ref-type="bibr" rid="b1">1</xref>,<xref ref-type="bibr" rid="b7">7</xref>,<xref ref-type="bibr" rid="b17">17</xref>). Trenutno poteka sicer intenzivno preučevanje vseh mehanizmov. Predvidevamo, da bodo rezultati teh raziskav pomembno prispevali k izboljšanju preprečevanja srčno-žilnih dogodkov pri bolnikih s sladkorno boleznijo.</p>
         </sec>
      </sec>
      <sec id="s6" sec-type="Neželeni učinki">
         <label>6</label>
         <title>Neželeni učinki</title>
         <p>V velikih raziskavah je bila pojavnost neželenih učinkov zaviralcev SGLT-2 podobna kot pri drugih skupinah antihiperglikemičnih zdravil. Ocenjujejo, da je bilo resnih neželenih učinkov med 1,0 in 12,6 % (<xref ref-type="bibr" rid="b6">6</xref>). Najpogostejši neželeni učinki zdravljenja z zaviralci SGLT-2 so okužbe sečil (vulvitis, vulvovaginitis, balanitis in balonopostitis). Okužbe spolovil je možno preprečevati z dobro higieno. Po drugi strani pa povečanega števila okužb sečil niso beležili (<xref ref-type="bibr" rid="b6">6</xref>). Povečano pojavnost genitalnih okužb pripisujejo povečanju količine glukoze v urinu, kar spodbuja razrast gliv in omogoča lažje množenje bakterij (<xref ref-type="bibr" rid="b1">1</xref>). Zaviralci SGLT-2 povzročajo tudi osmozno diurezo in zato relativno hipovolemijo, kar lahko vodi v ortostatsko hipotenzijo, ki se je v raziskavah pojavljala v manj kot 3 %. Možnost se poveča, če zaviralce SGLT-2 predpišemo ob že obstoječem diuretičnem zdravljenju (<xref ref-type="bibr" rid="b1">1</xref>,<xref ref-type="bibr" rid="b6">6</xref>). V izogib dehidraciji se zato priporoča dodatno zaužiti še vsaj 500 ml nesladkane tekočine dnevno (<xref ref-type="bibr" rid="b3">3</xref>). Zaviralci SGLT-2 tudi povečajo koncentracijo LDL, in sicer do 10 %, kar so beležili pri vseh predstavnikih skupine (povprečno zvišanje za 0,09 mmol/l) (<xref ref-type="bibr" rid="b3">3</xref>). Opisali so tudi minimalno zmanjšanje nastajanja kostnine in porast označevalcev kostne resorpcije, vendar ob tem ni bilo pomembnih sprememb v mineralni kostni gostoti (<xref ref-type="bibr" rid="b6">6</xref>). Ne glede na to, so v raziskavi CANVAS beležili do 23 % povečano pojavnost nizkoenergetskih zlomov, predvsem nadlakti in reber (<xref ref-type="bibr" rid="b17">17</xref>). Omenjeni pojav so pripisali manjšemu porastu serumskega fosfata. Izkazalo se je namreč, da zmanjšana reabsorpcija natrija v proksimalnem tubulu vodi v povečanje reabsorpcije natrija skupaj s fosfatom preko drugega prenašalca, ki se prav tako nahaja v proksimalnem tubulu. Neto učinek porasta serumskega fosfata je povečana aktivnost parathormona in povečana resorpcija kostnine, po drugi strani pa se iz enakega razloga zmanjša tvorba vitamina D ter absorpcija kalcija. Oboje vodi v zmanjšanje kostne gostote (<xref ref-type="bibr" rid="b20">20</xref>). Dodatno so za kanagliflozin pokazali, da povzroča minimalni porast serumske koncentracije kalija, predvsem pri bolnikih z okrnjenim ledvičnim delovanjem oz. pri tistih, ki so že prejemali zdravila z vplivom na koncentracijo kalija: običajno gre za zaviralce sistema renin-angiotenzin. Opisanega pojava pri empagliflozinu ali dapagliflozinu niso beležili. Neto porast seurmske koncentracije kalija je posledica nasprotujočih si mehanizmov, pri katerih prevlada učinek tistih, ki kalij zadržujejo (<xref ref-type="bibr" rid="b20">20</xref>).</p>
         <p>V raziskavi CANVAS so v skupini, ki je prejemala kanagliflozin, beležili dvakrat večje tveganje za amputacijo spodnjih udov v primerjavi s skupino, ki je prejemala placebo. Večjo pogostost amputacij so beležili pri moških in pri tistih, ki so že imeli amputacijo, nevropatijo ali periferno arterijsko bolezen. Stopnja tveganja za amputacijo ni bila odvisna od odmerka zdravila. Natančen vzrok ni poznan, domneva pa se, da bi bil razlog lahko povečana hemokoncentracija ob izraziti osmozni diurezi in hipovolemiji (<xref ref-type="bibr" rid="b17">17</xref>,<xref ref-type="bibr" rid="b19">19</xref>).</p>
         <p>Pri zdravljenju z zaviralci SGLT-2 so opisali tudi primere diabetične ketoacidoze. V veliki večini primerov je šlo za bolnike s sladkorno boleznijo tipa 1, ki so zaviralce SGLT-2 prejemali mimo odobrene indikacije, t. i. “off-label” indikacija. Opisani pa so tudi primeri pojava ketoacidoze pri bolnikih s sladkorno boleznijo tipa 2, ki se je pri večini pojavila ob sprožilnih dejavnikih, kot so akutna bolezen, okužbe, zmanjšan vnos hrane in tekočin, izpuščen odmerek insulina, kirurški posegi ali uživanje alkohola. Pri nekaterih so opažali nižje vrednosti glukoze, kot jih običajno zaznamo pri diabetični ketoacidozi, v nekaterih primerih pa je bila vrednost glukoze celo v evglikemičnem območju. Potencialni mehanizmi, preko katerih pride do nastanka ketoacidoze ob zdravljenju z zaviralci SGLT-2, so: povečanje razmerja glukagon-insulin, povečano nastajanje prostih maščobnih kislin, prehod iz oksidativne presnove ogljikovih hidratov na oksidativno presnovo prostih maščobnih kislin, zmanjšanje izločanja ketonskih telesc (<xref ref-type="bibr" rid="b1">1</xref>,<xref ref-type="bibr" rid="b22">22</xref>). Za preprečevanje nastanka diabetične ketoacidoze je potrebno zaviralec SGLT-2 ukiniti pred velikim načrtovanim kirurškim ali drugim invazivnim posegom, to je predvsem pred posegi, pri katerih se pričakuje velika izguba krvi, dehidracija oz. priprava na poseg lahko vodi v dehidracijo (npr. kolonoskopija). Iz enakih razlogov je potrebna opustitev zaviralca SGLT-2 pred večjo telesno dejavnostjo (npr. tek maratona). Priporoča se opustitev zadnjega odmerka vsaj 3 dni pred opisano dejavnostjo oz. vsaj 5 razpolovnih dob zdravila (<xref ref-type="bibr" rid="b23">23</xref>). V primeru, da gre za akutno bolezensko stanje (bruhanje, urgentna operacija, šokovno stanje, itd.), je potrebno zaviralce SGLT-2 takoj ukiniti (<xref ref-type="bibr" rid="b24">24</xref>). Po drugi strani pa jasnih priporočil za manjše, predvsem kontrastne preiskave, ni. Zdi pa se smiselno ukiniti zdravila pri kontrastnih preiskavah, pri katerih bi lahko pričakovali akutno ledvično okvaro, ki bi pripomogla k razvoju acidoze. V dosedanjih raziskavah zaključujejo, da gre pri ketoacidozi ob zdravljenju z zaviralci SGLT-2 za predvidljivo in zaznavno stanje, ki ga je mogoče preprečiti, pri čemer pa ne priporočajo rutinskega merjenja ketonov v urinu (<xref ref-type="bibr" rid="b1">1</xref>,<xref ref-type="bibr" rid="b22">22</xref>,<xref ref-type="bibr" rid="b24">24</xref>).</p>
         <p>Možno je, da je zdravljenje z zaviralci SGLT-2 povezano tudi s povečanjem tveganja za razvoj raka dojke in sečnega mehurja, vendar zaenkrat še ni jasnih zaključkov, predvsem glede na majhno število primerov in nejasnost, ali je bila maligna bolezen prisotna že pred pričetkom zdravljenja. Kljub temu priporočajo, da zdravljenja z zaviralci SGLT-2 ne uvajamo pri bolnikih, ki imajo znani rak mehurja (trenutno ali so ga preboleli v preteklosti) (<xref ref-type="bibr" rid="b1">1</xref>).</p>
      </sec>
      <sec id="s7" sec-type="Dostopnost v Sloveniji">
         <label>7</label>
         <title>Dostopnost v Sloveniji</title>
         <p>Zaviralci SGLT-2 so na mestu pri zdravljenju sladkorne bolezni tipa 2. V Sloveniji imamo trenutno na voljo dve zdravili iz te skupine, in sicer empagliflozin ter dapagliflozin.</p>
         <p>Empagliflozin je selektivni zaviralec SGLT-2. Se hitro absorbira, saj najvišjo plazemsko koncentracijo doseže 1–2 uri po zaužitju (<xref ref-type="bibr" rid="b25">25</xref>). Razpolovni čas v plazmi je 10,3–18,8 h. Priporočeni dnevni odmerek je 10–25 mg enkrat dnevno. Glede na trenutne smernice je potrebno pri okrnjenem delovanju ledvic odmerek zdravila prilagoditi, in sicer ko ocenjena glomerulna filtracija (oGF) upade pod 60 ml/min, je največji dovoljeni odmerek 10 mg dnevno. Ob oGF pod 45 ml/min je potrebno empagliflozin ukiniti oziroma je kontraindiciran. Pri oGF pod 60 ml/min empagliflozina ne smemo na novo uvajati. Pri jetrni okvari odmerka zdravila ni potrebno prilagajati, so pa klinične izkušnje na tem področju omejene (<xref ref-type="bibr" rid="b6">6</xref>,<xref ref-type="bibr" rid="b25">25</xref>). V Sloveniji je empagliflozin dostopen pod komercialnim imenom Jardiance in v fiksni kombinaciji z metforminom pod imenom Synjardy.</p>
         <p>Dapagliflozin je bolj selektiven za SGLT-2 kot SGLT-1. Po zaužitju se hitro absorbira, najvišjo plazemsko koncentracijo doseže 1–2 uri po zaužitju. Biološka uporabnost je 78 %. Presnova dapagliflozina poteka predvsem v jetrih in ledvicah z uridin difosfat-glukuroniltransferazo (UGT1A9). Priporočeni dnevni odmerek zdravila je 5–10 mg enkrat dnevno. Odmerek dapagliflozina je potrebno prilagoditi pri jetrni okvari, ko se priporoča znižanje odmreka z 10 mg na 5 mg dnevno. Glede na trenutne smernice je dapagliflozin kontraindiciran pri oGF pod 60 ml/min (<xref ref-type="bibr" rid="b6">6</xref>,<xref ref-type="bibr" rid="b25">25</xref>). V Sloveniji je dapagliflozin dostopen pod komercialnim imenom Forxiga, v fiksni kombinaciji z metforminom pa pod imenom Xigduo.</p>
         <sec id="s7.1" sec-type="Omejitve predpisovanja v Sloveniji">
            <label>7.1</label>
            <title>Omejitve predpisovanja v Sloveniji</title>
            <p>Glede na podatke iz svetovne literature lahko zaviralce SGLT-2 predpisujemo v monoterapiji ali v kombinaciji z drugimi antihiperglikemičnimi zdravili, kot so metformin, sulfonilsečnine, zaviralci dipeptidil peptidaze 4 (DPP-4) ali insulin (<xref ref-type="bibr" rid="b3">3</xref>).</p>
            <p>V Sloveniji je Zavod za zavarovanje Republike Slovenije (ZZZS) izdal pravila za predpisovanje zaviralcev SGLT-2 pri zdravljenju sladkorne bolezni tipa 2. Zaviralci SGLT-2 se glede na pravila ZZZS za zdravljenje sladkorne bolezni tipa 2 lahko predpišejo le v naslednjih primerih:</p>
            <list>
               <list-item>
                  <label>1.</label>
                  <p>v kombinaciji z metforminom ali pripravki sulfonilsečnine/repaglinidom pri kontraindikacijah za sulfonilsečnino/repaglinid oziroma metformin ali neželenih učinkih;</p>
               </list-item>
               <list-item>
                  <label>2.</label>
                  <p>v tritirnem zdravljenju z optimalnimi odmerki metformina in sulfonil/sečnine/repaglinida, kadar imata bolnik ali zdravnik zadržek za zdravljenje z insulinom ali</p>
               </list-item>
               <list-item>
                  <label>3.</label>
                  <p>v kombinaciji z insulinom in metforminom (ali brez metformina v primeru kontraindikacij za metformin ali neželenih učinkov).</p>
               </list-item>
            </list>
            <p>Zdravilo je možno predpisati le na osnovi izvida iz specialistične diabetološke ambulante s priporočilom za predpis zdravila (<xref ref-type="bibr" rid="b26">26</xref>).</p>
            <p>Glede na trenutna priporočila je uvedba SGLT-2 zaviralcev kontraindicirana pri oGF pod 60 ml/min. Empagliflozin lahko bolniki prejemajo v prilagojenen odmerku do oGF nad 45 ml/min. Glede na izsledke najnovejših raziskav pa izgleda, da se bo omejitev predpisovanja glede na oGF znižala ali je celo ne bo več.</p>
         </sec>
      </sec>
      <sec id="s8" sec-type="Potencial uporabe v prihodnosti">
         <label>8</label>
         <title>Potencial uporabe v prihodnosti</title>
         <p>Dosedanji ugodni učinki zaviralcev SGLT-2, ki segajo močno prek njihovega osnovnega delovanja na izboljšanje urejenosti glikemije, odpirajo velik spekter možnosti za njihovo širšo uporabo. Sladkorna bolezen že sama po sebi nosi veliko breme srčno-žilne ogroženosti. Zato je pri bolnikih s sladkorno boleznijo poleg dobro urejene glikemije še posebej pomembno, da jih tudi čim bolj zaščitimo pred srčno-žilnimi dogodki. Skupina SGLT-2 zaviralcev nam omogoča oboje. Prednost se kaže tudi pri bolnikih s sladkorno boleznijo, ki so srčno-žilni dogodek že utrpeli. Zaviralci SGLT-2 tudi ugodno vplivajo na ledvično delovanje, kar je še posebno dobrodošlo v začetnih stopnjah diabetične ledvične bolezni. Nenazadnje pa je pomemben tudi njihov vpliv na znižanje telesne mase, ki je pri večini bolnikov s sladkorno boleznijo tipa 2 nad normalno. Idealni kandidati za zdravljenje s zaviralci SGLT-2 bi bili torej bolniki s sladkorno boleznijo tipa 2 z visoko srčno-žilno ogroženostjo, ki so čezmerno prehranjeni in imajo vsaj začetno diabetično ledvično bolezen. Glede na dosedanje rezultate bi lahko pričakovali, da se bo mesto predpisovanja zaviralcev SGLT-2 zaradi vseh ugodnih učinkov povzpelo takoj za metformin; vendar je verjetno velika omejitev cena zdravila. Po drugi strani so potrebne tudi raziskave učinkov dolgotrajenga zdravljenja s zaviralci SGLT-2, ki do sedaj še niso bile opravljene, saj je ta skupina zdravil v klinični uporabi šele zadnjih nekaj let.</p>
      </sec>
      <sec id="s9" sec-type="Zaključek">
         <label>9</label>
         <title>Zaključek</title>
         <p>Zaviralci SGLT-2 so najnovejša skupina antihiperglikemičnih zdravil, ki so v dosedanjih raziskavah pokazali učinkovitost pri ureditvi glikemije, poleg tega imajo tudi druge ugodne presnovne učinke, predvsem znižanje telesne mase. Njihova prednost je tudi v tem, da delujejo po mehanizmu, ki je neodvisen od trebušne slinavke oz. insulina, zato ne povečajo tveganja za hipoglikemijo. Za empagliflozin in kanagliflozin so tudi pokazali, da ščitita pred nastankom srčno-žilnih dogodkov in njihovih zapletov. Zaviralci SGLT-2 so se že po nekaj letih klinične uporabe pokazali kot zelo obetavna skupina zdravil, potrebne pa so še nadaljnje raziskave za preučevanje predvsem dodatnih presnovnih in neželenih učinkov v sklopu dolgotrajnega zdravljenja.</p>
      </sec>
   </body>
   <back>
      <ref-list>
         <ref id="b1">
            <label>1. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Vallianou</surname>
                     <given-names>NG</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Geladari</surname>
                     <given-names>E</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Kazazis</surname>
                     <given-names>CE</given-names>
                  </name>
                    </person-group>. 
                    <article-title>SGLT-2 inhibitors: their pleiotropic properties</article-title>. 
                    <source>Diabetes Metab Syndr</source>. 
                    <year>2017</year>
                    <month>Oct - Dec</month>;
                    <volume>11</volume>(
                    <issue>4</issue>):
                    <fpage>311</fpage>–
                    <lpage>5</lpage>. 
                    <pub-id pub-id-type="doi">10.1016/j.dsx.2016.12.003</pub-id>
                    <pub-id pub-id-type="pmid">28011230</pub-id>
                    <issn>1871-4021</issn>
                </mixed-citation>
         </ref>
         <ref id="b2">
            <label>2. </label>
            <mixed-citation publication-type="webpage">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Diabetes Atlas</surname>
                     <given-names>ID</given-names>
                  </name>
                    </person-group>.
                    <source>IDF Diabetes Atlas</source>. 
                    <edition>8th edition 2017</edition>.
                    [<date-in-citation content-type="access-date" iso-8601-date="2017-03-22">cited 2017 Mar 22</date-in-citation>]. 
                    <comment>Available from:<uri>http://www.diabetesatlas.org/#</uri>
               </comment>.
                </mixed-citation>
         </ref>
         <ref id="b3">
            <label>3. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Storgaard</surname>
                     <given-names>H</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Gluud</surname>
                     <given-names>LL</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Bennett</surname>
                     <given-names>C</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Grøndahl</surname>
                     <given-names>MF</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Christensen</surname>
                     <given-names>MB</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Knop</surname>
                     <given-names>FK</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Benefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis</article-title>. 
                    <source>PLoS One</source>. 
                    <year>2016</year>
                    <month>Nov</month>;
                    <volume>11</volume>( 
                    <issue>11</issue>):
                    <fpage>e0166125</fpage>. 
                    <pub-id pub-id-type="doi">10.1371/journal.pone.0166125</pub-id>
                    <pub-id pub-id-type="pmid">27835680</pub-id>
                    <issn>1932-6203</issn>
                </mixed-citation>
         </ref>
         <ref id="b4">
            <label>4. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Ivo-Dos-Santos</surname>
                     <given-names>J</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Campos</surname>
                     <given-names>DL</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Galvão-Castro</surname>
                     <given-names>B</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Patterns of serologic response to human immunodeficiency virus type 1 (HIV-1) in Brazilians with different clinical forms of HIV infection</article-title>. 
                    <source>Mem Inst Oswaldo Cruz</source>. 
                    <year>1989</year>
                    <month>Jan-Mar</month>;
                    <volume>84</volume>(
                    <issue>1</issue>):
                    <fpage>9</fpage>–
                    <lpage>11</lpage>. 
                    <pub-id pub-id-type="doi">10.1590/S0074-02761989000100003</pub-id>
                    <pub-id pub-id-type="pmid">2319954</pub-id>
                    <issn>0074-0276</issn>
                </mixed-citation>
         </ref>
         <ref id="b5">
            <label>5. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Kalra</surname>
                     <given-names>S</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Singh</surname>
                     <given-names>V</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Nagrale</surname>
                     <given-names>D</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Sodium-Glucose Cotransporter-2 Inhibition and the Glomerulus: A Review</article-title>. 
                    <source>Adv Ther</source>. 
                    <year>2016</year>
                    <month>Sep</month>;
                    <volume>33</volume>(
                    <issue>9</issue>):
                    <fpage>1502</fpage>–
                    <lpage>18</lpage>. 
                    <pub-id pub-id-type="doi">10.1007/s12325-016-0379-5</pub-id>
                    <pub-id pub-id-type="pmid">27423646</pub-id>
                    <issn>0741-238X</issn>
                </mixed-citation>
         </ref>
         <ref id="b6">
            <label>6. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Kalra</surname>
                     <given-names>S</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors: A Review of Their Basic and Clinical Pharmacology</article-title>. 
                    <source>Diabetes Ther</source>. 
                    <year>2014</year>
                    <month>Dec</month>;
                    <volume>5</volume>(
                    <issue>2</issue>):
                    <fpage>355</fpage>–
                    <lpage>66</lpage>. 
                    <pub-id pub-id-type="doi">10.1007/s13300-014-0089-4</pub-id>
                    <pub-id pub-id-type="pmid">25424969</pub-id>
                    <issn>1869-6953</issn>
                </mixed-citation>
         </ref>
         <ref id="b7">
            <label>7. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Lioudaki</surname>
                     <given-names>E</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Androulakis</surname>
                     <given-names>ES</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Whyte</surname>
                     <given-names>M</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Stylianou</surname>
                     <given-names>KG</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Daphnis</surname>
                     <given-names>EK</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Ganotakis</surname>
                     <given-names>ES</given-names>
                  </name>
                    </person-group>. 
                    <article-title>The Effect of Sodium-Glucose Co-transporter-2 (SGLT-2) Inhibitors on Cardiometabolic Profile; Beyond the Hypoglycaemic Action</article-title>. 
                    <source>Cardiovasc Drugs Ther</source>. 
                    <year>2017</year>
                    <month>Apr</month>;
                    <volume>31</volume>(
                    <issue>2</issue>):
                    <fpage>215</fpage>–
                    <lpage>25</lpage>. 
                    <pub-id pub-id-type="doi">10.1007/s10557-017-6724-3</pub-id>
                    <pub-id pub-id-type="pmid">28444472</pub-id>
                    <issn>0920-3206</issn>
                </mixed-citation>
         </ref>
         <ref id="b8">
            <label>8. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Martens</surname>
                     <given-names>P</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Mathieu</surname>
                     <given-names>C</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Verbrugge</surname>
                     <given-names>FH</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Promise of SGLT2 Inhibitors in Heart Failure: diabetes and Beyond</article-title>. 
                    <source>Curr Treat Options Cardiovasc Med</source>. 
                    <year>2017</year>
                    <month>Mar</month>;
                    <volume>19</volume>(
                    <issue>3</issue>):
                    <fpage>23</fpage>. 
                    <pub-id pub-id-type="doi">10.1007/s11936-017-0522-x</pub-id>
                    <pub-id pub-id-type="pmid">28299616</pub-id>
                    <issn>1092-8464</issn>
                </mixed-citation>
         </ref>
         <ref id="b9">
            <label>9. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Zinman</surname>
                     <given-names>B</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Lachin</surname>
                     <given-names>JM</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Inzucchi</surname>
                     <given-names>SE</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes</article-title>. 
                    <source>N Engl J Med</source>. 
                    <year>2016</year>
                    <month>Mar</month>;
                    <volume>374</volume>(
                    <issue>11</issue>):
                    <fpage>1094</fpage>.
                    <pub-id pub-id-type="pmid">26981940</pub-id>
                    <issn>1533-4406</issn>
                </mixed-citation>
         </ref>
         <ref id="b10">
            <label>10. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Farahani</surname>
                     <given-names>P</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Non-severe Hypoglycemia Risk Difference between Sulfonylurea and Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2-I) as an Add-On to Metformin in Randomized Controlled Trials</article-title>. 
                    <source>J Popul Ther Clin Pharmacol</source>. 
                    <year>2017</year>
                    <month>May</month>;
                    <volume>24</volume>(
                    <issue>2</issue>):
                    <fpage>e32</fpage>–
                    <lpage>40</lpage>. 
                    <pub-id pub-id-type="doi">10.22374/1710-6222.24.2.6</pub-id>
                    <pub-id pub-id-type="pmid">28594482</pub-id>
                    <issn>1710-6222</issn>
                </mixed-citation>
         </ref>
         <ref id="b11">
            <label>11. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Cai</surname>
                     <given-names>X</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Yang</surname>
                     <given-names>W</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Gao</surname>
                     <given-names>X</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Chen</surname>
                     <given-names>Y</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Zhou</surname>
                     <given-names>L</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Zhang</surname>
                     <given-names>S</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>The Association Between the Dosage of SGLT2 Inhibitor and Weight Reduction in Type 2 Diabetes Patients: A Meta-Analysis</article-title>. 
                    <source>Obesity (Silver Spring)</source>. 
                    <year>2018</year>
                    <month>Jan</month>;
                    <volume>26</volume>(
                    <issue>1</issue>):
                    <fpage>70</fpage>–
                    <lpage>80</lpage>. 
                    <pub-id pub-id-type="doi">10.1002/oby.22066</pub-id>
                    <pub-id pub-id-type="pmid">29165885</pub-id>
                    <issn>1930-7381</issn>
                </mixed-citation>
         </ref>
         <ref id="b12">
            <label>12. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Ahmadieh</surname>
                     <given-names>H</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Azar</surname>
                     <given-names>S</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Effects of Sodium Glucose Cotransporter-2 Inhibitors on Serum Uric Acid in Type 2 Diabetes Mellitus</article-title>. 
                    <source>Diabetes Technol Ther</source>. 
                    <year>2017</year>
                    <month>Sep</month>;
                    <volume>19</volume>(
                    <issue>9</issue>):
                    <fpage>507</fpage>–
                    <lpage>12</lpage>. 
                    <pub-id pub-id-type="doi">10.1089/dia.2017.0070</pub-id>
                    <pub-id pub-id-type="pmid">28749169</pub-id>
                    <issn>1520-9156</issn>
                </mixed-citation>
         </ref>
         <ref id="b13">
            <label>13. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Shyangdan</surname>
                     <given-names>DS</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Uthman</surname>
                     <given-names>OA</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Waugh</surname>
                     <given-names>N</given-names>
                  </name>
                    </person-group>. 
                    <article-title>SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: a systematic review and network meta-analysis</article-title>. 
                    <source>BMJ Open</source>. 
                    <year>2016</year>
                    <month>Feb</month>;
                    <volume>6</volume>(
                    <issue>2</issue>):
                    <fpage>e009417</fpage>. 
                    <pub-id pub-id-type="doi">10.1136/bmjopen-2015-009417</pub-id>
                    <pub-id pub-id-type="pmid">26911584</pub-id>
                    <issn>2044-6055</issn>
                </mixed-citation>
         </ref>
         <ref id="b14">
            <label>14. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Cherney</surname>
                     <given-names>DZ</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Perkins</surname>
                     <given-names>BA</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Soleymanlou</surname>
                     <given-names>N</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Har</surname>
                     <given-names>R</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Fagan</surname>
                     <given-names>N</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Johansen</surname>
                     <given-names>OE</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus</article-title>. 
                    <source>Cardiovasc Diabetol</source>. 
                    <year>2014</year>
                    <month>Jan</month>;
                    <volume>13</volume>(
                    <issue>1</issue>):
                    <fpage>28</fpage>. 
                    <pub-id pub-id-type="doi">10.1186/1475-2840-13-28</pub-id>
                    <pub-id pub-id-type="pmid">24475922</pub-id>
                    <issn>1475-2840</issn>
                </mixed-citation>
         </ref>
         <ref id="b15">
            <label>15. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Fioretto</surname>
                     <given-names>P</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Zambon</surname>
                     <given-names>A</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Rossato</surname>
                     <given-names>M</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Busetto</surname>
                     <given-names>L</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Vettor</surname>
                     <given-names>R</given-names>
                  </name>
                    </person-group>. 
                    <article-title>SGLT2 Inhibitors and the Diabetic Kidney</article-title>. 
                    <source>Diabetes Care</source>. 
                    <year>2016</year>
                    <month>Aug</month>;
                    <volume>39</volume>
                    <supplement>Suppl 2</supplement>:
                    <fpage>S165</fpage>–
                    <lpage>71</lpage>. 
                    <pub-id pub-id-type="doi">10.2337/dcS15-3006</pub-id>
                    <pub-id pub-id-type="pmid">27440829</pub-id>
                    <issn>0149-5992</issn>
                </mixed-citation>
         </ref>
         <ref id="b16">
            <label>16. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Perrone-Filardi</surname>
                     <given-names>P</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Avogaro</surname>
                     <given-names>A</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Bonora</surname>
                     <given-names>E</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Colivicchi</surname>
                     <given-names>F</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Fioretto</surname>
                     <given-names>P</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Maggioni</surname>
                     <given-names>AP</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Mechanisms linking empagliflozin to cardiovascular and renal protection</article-title>. 
                    <source>Int J Cardiol</source>. 
                    <year>2017</year>
                    <month>Aug</month>;
                    <volume>241</volume>:
                    <fpage>450</fpage>–
                    <lpage>6</lpage>. 
                    <pub-id pub-id-type="doi">10.1016/j.ijcard.2017.03.089</pub-id>
                    <pub-id pub-id-type="pmid">28395981</pub-id>
                    <issn>0167-5273</issn>
                </mixed-citation>
         </ref>
         <ref id="b17">
            <label>17. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Rastogi</surname>
                     <given-names>A</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Bhansali</surname>
                     <given-names>A</given-names>
                  </name>
                    </person-group>. 
                    <article-title>SGLT2 Inhibitors Through the Windows of EMPA-REG and CANVAS Trials: A Review</article-title>. 
                    <source>Diabetes Ther</source>. 
                    <year>2017</year>
                    <month>Dec</month>;
                    <volume>8</volume>(
                    <issue>6</issue>):
                    <fpage>1245</fpage>–
                    <lpage>51</lpage>. 
                    <pub-id pub-id-type="doi">10.1007/s13300-017-0320-1</pub-id>
                    <pub-id pub-id-type="pmid">29076040</pub-id>
                    <issn>1869-6953</issn>
                </mixed-citation>
         </ref>
         <ref id="b18">
            <label>18. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Zinman</surname>
                     <given-names>B</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Wanner</surname>
                     <given-names>C</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Lachin</surname>
                     <given-names>JM</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Fitchett</surname>
                     <given-names>D</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Bluhmki</surname>
                     <given-names>E</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Hantel</surname>
                     <given-names>S</given-names>
                  </name>, 
                        <etal>et al</etal>; 
                        <collab>EMPA-REG OUTCOME Investigators</collab>
                    </person-group>. 
                    <article-title>Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes</article-title>. 
                    <source>N Engl J Med</source>. 
                    <year>2015</year>
                    <month>Nov</month>;
                    <volume>373</volume>(
                    <issue>22</issue>):
                    <fpage>2117</fpage>–
                    <lpage>28</lpage>. 
                    <pub-id pub-id-type="doi">10.1056/NEJMoa1504720</pub-id>
                    <pub-id pub-id-type="pmid">26378978</pub-id>
                    <issn>0028-4793</issn>
                </mixed-citation>
         </ref>
         <ref id="b19">
            <label>19. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Neal</surname>
                     <given-names>B</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Perkovic</surname>
                     <given-names>V</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Mahaffey</surname>
                     <given-names>KW</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>de Zeeuw</surname>
                     <given-names>D</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Fulcher</surname>
                     <given-names>G</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Erondu</surname>
                     <given-names>N</given-names>
                  </name>, 
                        <etal>et al</etal>; 
                        <collab>CANVAS Program Collaborative Group</collab>
                    </person-group>. 
                    <article-title>Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes</article-title>. 
                    <source>N Engl J Med</source>. 
                    <year>2017</year>
                    <month>Aug</month>;
                    <volume>377</volume>(
                    <issue>7</issue>):
                    <fpage>644</fpage>–
                    <lpage>57</lpage>. 
                    <pub-id pub-id-type="doi">10.1056/NEJMoa1611925</pub-id>
                    <pub-id pub-id-type="pmid">28605608</pub-id>
                    <issn>0028-4793</issn>
                </mixed-citation>
         </ref>
         <ref id="b20">
            <label>20. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Filippatos</surname>
                     <given-names>TD</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Tsimihodimos</surname>
                     <given-names>V</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Liamis</surname>
                     <given-names>G</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Elisaf</surname>
                     <given-names>MS</given-names>
                  </name>
                    </person-group>. 
                    <article-title>SGLT2 inhibitors-induced electrolyte abnormalities: an analysis of the associated mechanisms</article-title>. 
                    <source>Diabetes Metab Syndr</source>. 
                    <year>2018</year>
                    <month>Jan - Mar</month>;
                    <volume>12</volume>(
                    <issue>1</issue>):
                    <fpage>59</fpage>–
                    <lpage>63</lpage>. 
                    <pub-id pub-id-type="doi">10.1016/j.dsx.2017.08.003</pub-id>
                    <pub-id pub-id-type="pmid">28826578</pub-id>
                    <issn>1871-4021</issn>
                </mixed-citation>
         </ref>
         <ref id="b21">
            <label>21. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Lytvyn</surname>
                     <given-names>Y</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Bjornstad</surname>
                     <given-names>P</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Udell</surname>
                     <given-names>JA</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Lovshin</surname>
                     <given-names>JA</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Cherney</surname>
                     <given-names>DZ</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Sodium Glucose Cotransporter-2 Inhibition in Heart Failure: Potential Mechanisms, Clinical Applications, and Summary of Clinical Trials</article-title>. 
                    <source>Circulation</source>. 
                    <year>2017</year>
                    <month>Oct</month>;
                    <volume>136</volume>(
                    <issue>17</issue>):
                    <fpage>1643</fpage>–
                    <lpage>58</lpage>. 
                    <pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.117.030012</pub-id>
                    <pub-id pub-id-type="pmid">29061576</pub-id>
                    <issn>0009-7322</issn>
                </mixed-citation>
         </ref>
         <ref id="b22">
            <label>22. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Rosenstock</surname>
                     <given-names>J</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Ferrannini</surname>
                     <given-names>E</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Euglycemic Diabetic Ketoacidosis: A Predictable, Detectable, and Preventable Safety Concern With SGLT2 Inhibitors</article-title>. 
                    <source>Diabetes Care</source>. 
                    <year>2015</year>
                    <month>Sep</month>;
                    <volume>38</volume>(
                    <issue>9</issue>):
                    <fpage>1638</fpage>–
                    <lpage>42</lpage>. 
                    <pub-id pub-id-type="doi">10.2337/dc15-1380</pub-id>
                    <pub-id pub-id-type="pmid">26294774</pub-id>
                    <issn>0149-5992</issn>
                </mixed-citation>
         </ref>
         <ref id="b23">
            <label>23. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Goldenberg</surname>
                     <given-names>RM</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Berard</surname>
                     <given-names>LD</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Cheng</surname>
                     <given-names>AY</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Gilbert</surname>
                     <given-names>JD</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Verma</surname>
                     <given-names>S</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Woo</surname>
                     <given-names>VC</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>SGLT2 Inhibitor-associated Diabetic Ketoacidosis: Clinical Review and Recommendations for Prevention and Diagnosis</article-title>. 
                    <source>Clin Ther</source>. 
                    <year>2016</year>;
                    <month>Dec</month>;
                    <volume>38</volume>(
                    <issue>12</issue>):
                    <fpage>2654</fpage>–
                    <lpage>64</lpage>. 
                    <pub-id pub-id-type="doi">10.1016/j.clinthera.2016.11.002</pub-id>
                    <pub-id pub-id-type="pmid">28003053</pub-id>
                    <issn>0149-2918</issn>
                </mixed-citation>
         </ref>
         <ref id="b24">
            <label>24. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Handelsman</surname>
                     <given-names>Y</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Henry</surname>
                     <given-names>RR</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Bloomgarden</surname>
                     <given-names>ZT</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Dagogo-Jack</surname>
                     <given-names>S</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>DeFronzo</surname>
                     <given-names>RA</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Einhorn</surname>
                     <given-names>D</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>American Association of Clinical Endocrinologists and American College of Endocrinology Position Statement on the Association of Sglt-2 Inhibitors and Diabetic Ketoacidosis</article-title>. 
                    <source>Endocr Pract</source>. 
                    <year>2016</year>
                    <month>Jun</month>;
                    <volume>22</volume>(
                    <issue>6</issue>):
                    <fpage>753</fpage>–
                    <lpage>62</lpage>. 
                    <pub-id pub-id-type="doi">10.4158/EP161292.PS</pub-id>
                    <pub-id pub-id-type="pmid">27082665</pub-id>
                    <issn>1530-891X</issn>
                </mixed-citation>
         </ref>
         <ref id="b25">
            <label>25. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Scheen</surname>
                     <given-names>AJ</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus</article-title>. 
                    <source>Drugs</source>. 
                    <year>2015</year>
                    <month>Jan</month>;
                    <volume>75</volume>(
                    <issue>1</issue>):
                    <fpage>33</fpage>–
                    <lpage>59</lpage>. 
                    <pub-id pub-id-type="doi">10.1007/s40265-014-0337-y</pub-id>
                    <pub-id pub-id-type="pmid">25488697</pub-id>
                    <issn>0012-6667</issn>
                </mixed-citation>
         </ref>
         <ref id="b26">
            <label>26. </label>
            <mixed-citation publication-type="book">
                    <person-group person-group-type="editor">
                        <name name-style="western">
                     <surname>Zaletel</surname>
                     <given-names>J</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Ravnik Oblak</surname>
                     <given-names>M</given-names>
                  </name>, 
                        <role>eds</role>
                    </person-group>. 
                    <source>Slovenske smernice za klinično obravnavo sladkorne bolezni tipa 2</source>. 
                    <edition>3th ed</edition>. 
                    <publisher-loc>Ljubljana</publisher-loc>:
                    <publisher-name>Klinični oddelek za endokrinologijo, diabetes in presnovne bolezni; Interna klinika UKC Ljubljana in Klinični oddelek za endokrinologijo, diabetes in bolezni presnove; Pediatrična klinika Ljubljana</publisher-name>;
                    <year>2016</year>.
                </mixed-citation>
         </ref>
      </ref-list>
   </back>
   <sub-article id="article-en" xml:lang="en" article-type="other">
      <front-stub>
         <article-categories>
            <subj-group subj-group-type="discipline" xml:lang="en">
               <subject>Medicine and health sciences</subject>
               <subj-group>
                  <subject>Metabolic and hormonal disorders</subject>
               </subj-group>
            </subj-group>
            <subj-group subj-group-type="discipline" xml:lang="sl">
               <subject>Medicina/Zdravstvo</subject>
               <subj-group>
                  <subject>Metabolne in hormonske motnje</subject>
               </subj-group>
            </subj-group>
            <subj-group subj-group-type="article-type" xml:lang="en">
               <subject>Professional article</subject>
            </subj-group>
            <subj-group subj-group-type="article-type" xml:lang="sl">
               <subject>Strokovni članek</subject>
            </subj-group>
            <subj-group subj-group-type="heading" xml:lang="en">
               <subject>Metabolic and hormonal disorders</subject>
            </subj-group>
         </article-categories>
         <title-group>
            <article-title xml:lang="en">SGLT-2 inhibitors: a novelty in the treatment of type 2 diabetes</article-title>
            <alt-title alt-title-type="running-head" xml:lang="en">Zaviralci SGLT-2</alt-title>
         </title-group>
         <contrib-group>
            <contrib contrib-type="author" xlink:type="simple">
               <name name-style="western">
                  <surname>Lunder</surname>
                  <given-names>Mojca</given-names>
               </name>
               <xref ref-type="aff" rid="en-aff1">1</xref>
            </contrib>
            <contrib contrib-type="author" xlink:type="simple">
               <name name-style="western">
                  <surname>Janić</surname>
                  <given-names>Miodrag</given-names>
               </name>
               <xref ref-type="aff" rid="en-aff2">2</xref>
            </contrib>
            <contrib contrib-type="author" xlink:type="simple">
               <name name-style="western">
                  <surname>Šabovič</surname>
                  <given-names>Mišo</given-names>
               </name>
               <xref ref-type="aff" rid="en-aff2">2</xref>
            </contrib>
            <contrib contrib-type="author" xlink:type="simple">
               <name name-style="western">
                  <surname>Janež</surname>
                  <given-names>Andrej</given-names>
               </name>
               <xref ref-type="aff" rid="en-aff1">1</xref>
            </contrib>
         </contrib-group>
         <aff id="en-aff1" xml:lang="en">
            <label>1</label>
            <institution>Department of Endocrinology, Diabetes and Metabolic Diseases, Division of Internal Medicine, University Medical Centre Ljubljana, Ljubljana, Slovenia</institution>
         </aff>
         <aff id="en-aff2" xml:lang="en">
            <label>2</label>
            <institution>Department of Vascular Diseases, Division of Internal Medicine, University Medical Centre Ljubljana, Ljubljana, Slovenia</institution>
         </aff>
         <abstract xml:lang="en">
            <title>Abstract</title>
            <p>Sodium glucose co-transporter-2 (SGLT-2) inhibitors are the newest group of drugs for the treatment of type 2 diabetes mellitus, which have been in clinical use for the past few years. They act in the proximal renal tubules by reducing the glucose reabsorption, the glucose then being excreted in the urine. Consequently, by decreasing blood glucose levels, they exert a favourable effect on the glycaemic control and importantly, do not increase the risk of hypoglycaemia. SGLT-2 inhibitors also possess favourable metabolic effects, especially on weight, blood pressure and serum uric acid level reduction. They also slow down the progression of diabetic kidney disease. For some SGLT-2 inhibitors it was shown that they exert beneficial effects on the cardiovascular system by reducing cardiovascular events and complications through yet unknown mechanisms, which are subject of intensive research. SGLT-2 inhibitors rarely cause serious side effects. This manuscript describes the mechanism of action of SGLT-2 inhibitors, their effect on the glycaemic control, metabolic effects, effects on the incidence of cardiovascular disease, as well as the most common adverse effects and prescribing restrictions for SGLT-2 inhibitors in Slovenia.</p>
         </abstract>
      </front-stub>
      <body>
         <sec id="en-s1" sec-type="Introduction">
            <label>1</label>
            <title>Introduction</title>
            <p>Diabetes is a metabolic disease characterised by chronically increased blood glucose levels. The incidence of diabetes has been increasing and has reached pandemic proportions. It was estimated that in 2017 there were 425 million adults with diabetes in the world. The number of patients with diabetes is predicted to rise to 642 million by 2040. Additionally, by 2025, the number of deaths attributable to diabetes and its complications will increase by 50 % (<xref ref-type="bibr" rid="en-b1">1</xref>,<xref ref-type="bibr" rid="en-b2">2</xref>).</p>
            <p>As the available medications do not provide optimal glycaemic control, there is a need for the development of new antihyperglycaemic drugs. Sodium-glucose co-transporter 2 (SGLT-2) inhibitors represent a novel approach to the management of type 2 diabetes. They were approved by the Food and Drug Administration (FDA) and European Medicines Agency (EMA) between 2012 and 2014 (<xref ref-type="bibr" rid="en-b3">3</xref>). The first SGLT-2 inhibitor was phlorizin, which was extracted from the bark of apple trees. This molecule has been known for more than 200 years. It is a non-selective inhibitor of both SGLT-2 and SGLT-1. Phlorizin provides effective glycaemic control and reduces insulin resistance in diabetic animals. Clinical use of this drug is restricted by its poor absorption after oral administration, as well as by nausea and diarrhea due to SGLT-1 inhibition. Its metabolic product, phloretin, also inhibits the glucose transporter type 1 (GLUT-1) expressed in erythrocytes and blood-brain barrier. Nevertheless, the phlorizin molecule was succesfully used as the basis for synthesis of several selective SGLT-2 inhibitors, such as empagliflozin, dapagliflozin, canagliflozin and others (<xref ref-type="bibr" rid="en-b1">1</xref>).</p>
         </sec>
         <sec id="en-s2" sec-type="Mechanism of action">
            <label>2</label>
            <title>Mechanism of action</title>
            <p>In individuals without diabetes, 180 g of glucose is filtered by the renal glomerulus, daily, and virtually all of it is subsequently reabsorbed in the proximal tubule. Thereby the kidney prevents glucose loss (<xref ref-type="bibr" rid="en-b1">1</xref>,<xref ref-type="bibr" rid="en-b4">4</xref>). Once the renal threshold for glucose is exceeded in healthy individuals, i.e with glucose levels above 11 mmol/L, glycosuria results (<xref ref-type="bibr" rid="en-b5">5</xref>). This protective action of the kidney prevents further increase in plasma glucose and the associated harmful effects (<xref ref-type="bibr" rid="en-b6">6</xref>).</p>
            <p>In the proximal renal tubule, glucose can be reabsorbed passively via GLUT transporters or actively via SGLT transporters (<xref ref-type="bibr" rid="en-b4">4</xref>,<xref ref-type="bibr" rid="en-b6">6</xref>). The latter transports glucose into the cells using sodium gradient created by Na/K ATPase pump at the basolateral border of the cell membranes (<xref ref-type="bibr" rid="en-b1">1</xref>). SGLT transporter has two variants: SGLT-1 and SGLT-2. SGLT-1 is found mostly in the small intestine, kidney, heart and skeletal muscles, where it is responsible for active absorption of glucose into these tissues. SGLT-2 is found almost exclusively in the proximal renal tubules, where it reabsorbs 80–90 % of the filtered glucose load. SGLT-1 is responsible for less than 10 % of the glucose reabsorption in kidneys (<xref ref-type="bibr" rid="en-b4">4</xref>-<xref ref-type="bibr" rid="en-b7">7</xref>). It has been demonstrated that the number of SGLT-2 transporters is increased in diabetic patients (<xref ref-type="bibr" rid="en-b1">1</xref>). With rising plasma glucose concentrations, kidneys‘ SGLT-2 expression increases, causing an increased renal threshold for glycosuria. Additionally, this causes enhanced renal glucose reabsorption in proximal tubules, which leads to further elevation of its plasma levels (<xref ref-type="bibr" rid="en-b5">5</xref>).</p>
            <p>SGLT-2 inhibitors act by inhibiting SGLT-2 in the proximal tubules, thereby preventing glucose reabsorption. Increased urinary glucose excretion lowers its plasma concentrations, leading to efficient glycaemic control (<xref ref-type="bibr" rid="en-b8">8</xref>). SGLT-2 inhibitors induce urinary excretion of 20–100 g of glucose and cause a daily loss of 90–450 kcal (<xref ref-type="bibr" rid="en-b4">4</xref>). The efficacy of SGLT-2 inhibitors depends on the plasma glucose levels: low glucose levels reduce their efficacy. The decrease in glucose levels caused by SGLT-2 inhibitors in non-diabetic individuals differs from that in patients with diabetes. SGLT-2 inhibitors act independently of insulin secretion and therefore do not cause beta-cells failure nor do they increase the risk for hypoglycaemia (<xref ref-type="bibr" rid="en-b6">6</xref>). The mechanism of action of SGLT-2 inhibitors is presented in <xref ref-type="fig" rid="en-fig1">Figure 1</xref>.</p>
            <fig position="anchor" id="en-fig1" orientation="portrait">
               <label>Figure 1:</label>
               <caption>
                  <p> Schematic presentation of SGLT-2 inhibitor action in the renal glomerulus and proximal tubule. Adopted by (<xref ref-type="bibr" rid="en-b5">5</xref>).</p>
               </caption>
               <p>
                  <graphic xlink:href="2705-en-web-resources/image/zdravvestn-2705-en-01.png"
                           position="float"
                           orientation="portrait"/>
               </p>
            </fig>
         </sec>
         <sec id="en-s3" sec-type="Basic antihyperglycaemic effects">
            <label>3</label>
            <title>Basic antihyperglycaemic effects</title>
            <p>Several previous studies have shown that SGLT-2 inhibitors decrease HbA1c. This was dependent on the baseline values: HbA1c droped by 0.51–1.45 % with the baseline HbA1c of 7–9.1 % (<xref ref-type="bibr" rid="en-b1">1</xref>). A mean reduction in HbA1c levels induced by SGLT-2 inhibitors was 0.69 % compared to placebo (<xref ref-type="bibr" rid="en-b3">3</xref>). In the »Empagliflozin Cardiovascular Outcomes and Mortality in Type 2 Diabetes« (EMPA-REG OUTCOME) trial, empagliflozin 10 mg daily decreased HbA1c levels by only 0.54 %, and empagliflozin 25 mg daily by 0.6 % (<xref ref-type="bibr" rid="en-b9">9</xref>). Treatment with SGLT-2 inhibitors was reported to reduce fasting glucose levels by an average of 0.9 mmol/L as compared to placebo (<xref ref-type="bibr" rid="en-b3">3</xref>).</p>
            <p>The rate of hypoglycaemic episodes in patients treated with SGLT-2 inhibitors did not exceed that in placebo groups. This may be due to the insulin-independent action of these drugs. In addition, the effects of SGLT-2 inhibitors decrease when the plasma glucose levels are decreasing thereby preventing hypoglycaemia (<xref ref-type="bibr" rid="en-b5">5</xref>). The rate of hypoglicaemia was higher in patients taking SGLT-2 inhibitors in combination with other glucose-lowering drugs that may cause hypoglycaemia, such as sulfonylureas or insulin (<xref ref-type="bibr" rid="en-b6">6</xref>). SGLT-2 inhibitors caused statistically less mild hypoglycaemia episodes than sulfonylureas, their rate being higher by 30 % in patients taking sulfonylureas than in patients taking placebo (<xref ref-type="bibr" rid="en-b10">10</xref>). A meta-analysis showed that the incidence of mild hypoglycaemia in the treatment with dapagliflozin and empagliflozin was low and comparable with placebo (<xref ref-type="bibr" rid="en-b3">3</xref>). <xref ref-type="fig" rid="en-fig2">Figure 2</xref> summarizes basic, additional favourable and adverse effects of SGLT-2 inhibitors (see further text).</p>
            <fig position="anchor" id="en-fig2" orientation="portrait">
               <label>Figure 2:</label>
               <caption>
                  <p> Overview of basic effects, additional beneficial effects and adverse effects of SGLT-2 inhibitors. HDL – high density lipoprotein, TG – triglycerides, HbA1c – glycated haemoglobin, LDL – low density lipoprotein.</p>
               </caption>
               <p>
                  <graphic xlink:href="2705-en-web-resources/image/zdravvestn-2705-en-02.png"
                           position="float"
                           orientation="portrait"/>
               </p>
            </fig>
         </sec>
         <sec id="en-s4" sec-type="Favourable metabolic effects">
            <label>4</label>
            <title>Favourable metabolic effects</title>
            <sec id="en-s4.1" sec-type="Reduction of body mass">
               <label>4.1</label>
               <title>Reduction of body mass</title>
               <p>Patients receiving SGLT-2 inhibitor lose 1–5 kg, which usually represents 2–5 % of their body mass. A greater loss was recorded in patients with long-standing diabetes and higher baseline body mass (<xref ref-type="bibr" rid="en-b6">6</xref>). Lioudaki et al. found that the effects of SGLT-2 inhibitors on weight loss are dose-dependent: body weight loss of 1.61 kg was reported with lower doses, and a loss of 2.66 kg with higher doses. Importanlty, weight loss was associated with a decrease in waist circumference (<xref ref-type="bibr" rid="en-b7">7</xref>). Another meta-analysis demonstrated that treatment with SGLT-2 inhibitors led to significant loss of body weight: by 1.3–2.24 kg with dapagliflozin and by 1.84–1.93 kg with empagliflozin. A statistically significant association between weight reduction and higher doses was reported for dapagliflozin but not for empagliflozin (<xref ref-type="bibr" rid="en-b11">11</xref>). Weight gain due to insulin treatment was prevented when SGLT-2 inhibitor was added (<xref ref-type="bibr" rid="en-b6">6</xref>).</p>
               <p>During the initial 12–26 weeks of treatment with SGLT-2 inhibitors, a fast body weight loss was recorded, whereafter it stopped or showed only a minimal decrease. Body weight reduction in the initial period seems to be due to the loss of fluid through osmotic diuresis, and later on due to the loss of body fat. Dual energy x-ray absorptiometry (DEXA) measurements demonstrated that 30 % of body weight loss was caused by osmotic diuresis and 70 % of weight loss was attributable to loss of adipose tissue (mostly visceral and, to a lesser extent, subcutaneous tissue) (<xref ref-type="bibr" rid="en-b1">1</xref>). The most probable cause of body fat loss is a metabolic shift from carbohydrate to lipid utilization mediated by SGLT-2 inhibitors, which leads to enhanced glucose excretion and the resulting relative glucose deficiency (<xref ref-type="bibr" rid="en-b1">1</xref>). The effects of SGLT-2 inhibitors on body weight reduction are not yet fully understood. A greater weight loss would be expected considering that in patients treated with SGLT-2 inhibitors, up to 100 g of glucose is excreted in the urine per day (<xref ref-type="bibr" rid="en-b11">11</xref>).</p>
            </sec>
            <sec id="en-s4.2" sec-type="Lowering of uric acid levels">
               <label>4.2</label>
               <title>Lowering of uric acid levels</title>
               <p>Many patients with type 2 diabetes have elevated serum uric acid levels, which may be responsible for chronic complications of diabetes (<xref ref-type="bibr" rid="en-b6">6</xref>,<xref ref-type="bibr" rid="en-b12">12</xref>). SGLT-2 inhibitors lower serum uric acid levels by 10–13 %; a greater decrease occurring in individuals with higher baseline values (<xref ref-type="bibr" rid="en-b7">7</xref>). Therapy with canagliflozin normalised uric acid levels in 20–30 % of patients with elevated uric acid. Dapagliflozin also lowered uric acid levels, but the effect wore off after treatment discontinuation. Empagliflozin was also shown to posess uric acid-lowering effect (<xref ref-type="bibr" rid="en-b12">12</xref>). The most probable mechanism is enhanced glycosuria with the resulting exchange of uric acid at the apical membrane of the proximal tubular cell, and increased excretion of uric acid in the urine, most likely due to the effect on the uric acid transport in the renal proximal tubules, e.g. GLUT-9 (<xref ref-type="bibr" rid="en-b12">12</xref>).</p>
            </sec>
            <sec id="en-s4.3" sec-type="Effects on fat metabolism">
               <label>4.3</label>
               <title>Effects on fat metabolism</title>
               <p>Individuals with type 2 diabetes usually have increased triglyceride levels, low levels of high-density lipoproteins (HDL) and high levels of low-density lipoproteins (LDL). Patients treated with SGLT-2 inhibitors showed mild reduction of triglyceride levels and an increase in the HDL levels. The mechanisms responsible for these changes most likely include weight loss and decrease in glucose levels, leading to reduced production of very low density lipoproteins (VLDL) in the liver. Consequently, plasma triglyceride levels decrease (<xref ref-type="bibr" rid="en-b7">7</xref>). In comparison with placebo, SGLT-2 inhibitors increase HDL levels by 0.05 mmol/L, and are expected to reduce triglyceride levels by 0.09 mmol/L (<xref ref-type="bibr" rid="en-b3">3</xref>). On the other hand, an increase in LDL levels, which is linked to higher risk for cardiovascular diseases, is one of adverse effects associated with SGLT-2 inhibitor therapy.</p>
            </sec>
            <sec id="en-s4.4" sec-type="Effects on hepatic function">
               <label>4.4</label>
               <title>Effects on hepatic function</title>
               <p>SGLT-2 inhibitors decrease alanine aminotransferase (ALT) levels by 2.8 IU/L, thereby exerting a beneficial effect on non-alcoholic fatty liver disease. Whether ALT reduction is due to the body weight decrease caused by SGLT-2 inhibitors or it occurs because of their direct effects on the liver remains unclear (<xref ref-type="bibr" rid="en-b3">3</xref>).</p>
            </sec>
         </sec>
         <sec id="en-s5" sec-type="Beneficial non-metabolic effects">
            <label>5</label>
            <title>Beneficial non-metabolic effects</title>
            <sec id="en-s5.1" sec-type="Blood pressure reduction">
               <label>5.1</label>
               <title>Blood pressure reduction</title>
               <p>SGLT-2 inhibitors were shown to significantly reduce systolic and diastolic blood pressure in several studies. A larger decrease was observed for systolic blood pressure and this correlated with the active substance and dosage of the SGTL-2 inhibitor used. The effect on blood pressure did not depend on the degree of glycaemic control and weight loss (noted soon after the initiation of SGLT-2 inhibitor treatment). Greater decrease of blood pressure occured in patients with higher baseline systolic blood pressures (<xref ref-type="bibr" rid="en-b6">6</xref>,<xref ref-type="bibr" rid="en-b7">7</xref>). In their meta-analysis, Shyangdana et al. showed that SGLT-2 inhibitors used as monotherapy or in combination with metformin led to decreased blood pressure compared to placebo; i.e. to –2.6 mmHg by empagliflozin 10 mg/day, and to –6 mmHg by canagliflozin 300 mg/day. The same study showed that SGLT-2 inhibitors induced a mean decrease in systolic pressure of –3.77 mmHg and a mean decrease in diastolic pressure of –1.75 mmHg. It should be emphasized that blood pressure reduction caused by SGLT-2 inhibitors was not associated with increase in heart rate (<xref ref-type="bibr" rid="en-b13">13</xref>). The greatest decrease in blood pressure was seen in patients treated with canagliflozin (<xref ref-type="bibr" rid="en-b3">3</xref>).</p>
               <p>Primary mechanisms involved in blood pressure reduction seem to include osmotic diuresis and enhanced urinary sodium excretion (decreased amount of sodium in the body). Increased delivery of sodium to the macula densa with SGLT-2 inhibition reduces renin secretion and in the long term leads to inhibition of the renin-angiotensin-aldosterone system with beneficial effects on blood pressure. The absence of heart rate increase supports this theory (<xref ref-type="bibr" rid="en-b7">7</xref>). Reduction of arterial stiffness is another factor contributing to a decrease in blood pressure, as shown in young patients with type 1 diabetes (<xref ref-type="bibr" rid="en-b14">14</xref>).</p>
            </sec>
            <sec id="en-s5.2" sec-type="Renoprotective effects">
               <label>5.2</label>
               <title>Renoprotective effects</title>
               <p>SGLT-2 inhibitors provide renal protection by improving glycaemic control, reducing blood pressure, and most probably, by exerting direct effects on the kidney (reduction of glomerular hyperfiltration, inflammation and fibrosis). Progression of diabetic nephropathy is associated with a gradual decrease in glomerular filtration rate (GFR), leading to reduced efficacy of SGLT-2 inhibitors. In patients with GFR &lt; 45 ml/min, their effects on HbA1c eventually disappear, but they continue to exert other non-metabolic effects (<xref ref-type="bibr" rid="en-b15">15</xref>).</p>
               <p>Diabetic nephropathy develops due to several factors. The mechanisms responsible for the development of glomerular hyperfiltration include impaired neurohumural activation (haemodynamic effect) and tubular factors. The former involves a decrease in afferent arteriole tone compared to the efferent one, and increase in intraglomerular pressure, leading to glomerular hyperfiltration. This is due to increased activity of angiotensin II with affinity for efferent arteriole constriction. Another mechanism involves increase in glucose burden in the proximal renal tubule and the associated SGLT-2 and SGLT-1 hyperactivity and increased glucose and sodium reabsorption in the proximal tubules, with the resulting activation of tubulo-glomerular feedback because of diminshed delivery of sodium to the macula densa in the distal tubule of the nephron. As a result, vasodilation of the afferent arteriole and glomeular hyperfiltration occur. Hyperfiltration is followed by a progressive decrease in GFR. At early stages, hyperfiltration causes glomerulosclerosis, and the compensatorily increased filtration rate in other, previously unaffected glomeruli, leads to sclerosis of these glomeruli too (<xref ref-type="bibr" rid="en-b1">1</xref>,<xref ref-type="bibr" rid="en-b6">6</xref>,<xref ref-type="bibr" rid="en-b15">15</xref>).</p>
               <p>SGLT-2 inhibitors increase delivery of the filtered burden, especially sodium, to the distal nephron segment and macula densa, thereby enhancing local adenosine excretion leading to adenosine-induced constriction of the afferent arteriole. The resulting decrease in intraglomerulal pressure and GFR has protective glomerular effects (<xref ref-type="bibr" rid="en-b15">15</xref>,<xref ref-type="bibr" rid="en-b16">16</xref>). Empagliflozin has been shown to reduce inflammation and decrease the level of renal fibrosis due to improved glycaemic control, thereby limiting glucose-induced impairment of proximal renal tubules. Also, it was found that the treatment with SGLT-2 inhibitors for 24 weeks decreased urinary albumin-creatinine ratio in patients with diabetes and albuminuria by 41 % compared to placebo (<xref ref-type="bibr" rid="en-b7">7</xref>). Thanks to the above described mechanisms, the use of SGLT-2 inhibitors in combination with angiotensine-converting enzyme inhibitors has proved to be the most effective way to prevent progression of diabetic nephropathy and is superior to the use of a single drug (<xref ref-type="bibr" rid="en-b1">1</xref>).</p>
            </sec>
            <sec id="en-s5.3" sec-type="Cardiovascular benefits">
               <label>5.3</label>
               <title>Cardiovascular benefits</title>
               <p>According to the requirements issued by the FDA in 2008, all new glucose-lowering drugs should be investigated for their potential cardiovascular risks. Two such studies have been conducted so far for SGLT-2 inhibitors, i.e the EMPA-REG OUTCOME trial for empagliflozin and the Canagliflozin Cardiovascular Assessment Study (CANVAS) for canagliflozion, both in patients with type 2 diabetes. The studies differed in that the EMPA-REG OUTCOME trial included 99.5 % of patients who had suffered a previous cardiovascular event, and the CANVAS study included only 67 % of such patients. The primary aim of both studies was to determine the effect of SGLT-2 inhibitors on the following three major adverse cardiovascular events (MACE): cardiovascular death, non-fatal myocardial infarction and non-fatal stroke. The results of both investigations confirmed the efficacy of SGLT-2 inhibitors, which decreased MACE by 14 % as compared to placebo. Yet, a difference was found between the two drugs when concerning the individual elements of MACE. In the EMPA-REG OUTCOME study the cardiovascular mortality decreased by 38 % during the study period (3.1 years), whereas in the CANVAS trial by 13 % during the study period (6.0 years). There seem to be several reasons for these results: different characteristics of the patients studied (different proportions of cardiovascular patients), effects of other cardioprotective drugs, selectivity of SGLT-2 inhibitors for SGLT-2 versus SGLT-1 (&gt; 2500-fold for empagliflozin and &gt; 250-fold for canagliflozin), and statistical analysis. Also, there was a difference in the time to the separation of survival curves. Based on data of the EMPA-REG OUTCOME the effect was noted early, i.e. after three months, and was attributed to haemodynamic effects, hypothesis of changes in cardiac fuel, improved fat metabolism and improved endothelial function. In the CANVAS trial these results were recorded later, i.e.after one year, which is attributable to positive effects of canagliflozin which slowed the progression of atherosclerosis (<xref ref-type="bibr" rid="en-b1">1</xref>,<xref ref-type="bibr" rid="en-b7">7</xref>,<xref ref-type="bibr" rid="en-b17">17</xref>-<xref ref-type="bibr" rid="en-b19">19</xref>). Importantly, in both groups treated with SGLT-2 inhibitors significanly less patients were hospitalised for heart failure compared to those receiving placebo: 35 % in EMPA-REG OUTCOME and 33 % in CANVAS trial (<xref ref-type="bibr" rid="en-b17">17</xref>-<xref ref-type="bibr" rid="en-b19">19</xref>). The described beneficial effects cannot be explained solely by the impact of drugs on glycaemia. It is assumed that the benefit is independent of glycaemic control, yet further studies are needed. In previous studies, it was shown that SGLT-2 inhibitors decrease plasma volume, enhance urinary sodium excretion and improve the response to diuretic therapy. In addition, they enhance a metabolic shift to improved myocardial bioenergetics (improved balance between oxygen consumption and work efficiency with ketone bodies utilization as compared to glucose). An interesting and important cardiovascular protective mechanism involves the increase in serum magnesium levels. The role of magnesium in protecting the myocardium against significant arrhythmias is well established (<xref ref-type="bibr" rid="en-b20">20</xref>). Thanks to their renoprotective action, SGLT-2 inhibitors reduce the degree of renal failure in patients with heart failure. Beneficial effects on endothelial function are also important. Thanks to the above decribed effects, SGLT-2 inhibitors may be an effective treatment option for patients with heart failure with preserved ejection fraction, for whom no such treatment has been available so far (<xref ref-type="bibr" rid="en-b8">8</xref>,<xref ref-type="bibr" rid="en-b21">21</xref>).</p>
               <p>The mechanisms underlying positive cardiovascular effects of SGLT-2 inhibitors have not yet been fully investigated. Most probably, cardiac overload and oxygen consumption are reduced through lowered arterial pressure and decreased arterial stiffness, which decreases myocardial oxygen consumption and improves cardiac function. In addition, effects of protective mechanisms involved in SGLT-2 inhibition include body weight reduction, absence of stimulatory effect on sympathetic nervous activity, increase in urinary sodium excretion, reduction of oxidative stress, stimulation of glucagon excretion and other beneficial effects mediated by as-yet unidentified mechanisms of action (<xref ref-type="bibr" rid="en-b1">1</xref>,<xref ref-type="bibr" rid="en-b7">7</xref>,<xref ref-type="bibr" rid="en-b17">17</xref>).</p>
               <p>An intensive research effort is currently underway to identify these mechanisms. The results obtained are expected to significantly contribute to improved prevention of cardiovascular events in patients with diabetes.</p>
            </sec>
         </sec>
         <sec id="en-s6" sec-type="Adverse effects">
            <label>6</label>
            <title>Adverse effects</title>
            <p>The rate of adverse effects associated with SGLT-2 inhibitors reported by large-scale studies was similar to that found for other groups of antihyperglycaemic agents. It is estimated that serious adverse effects occur in 1.0 % to 12.6 % of cases (<xref ref-type="bibr" rid="en-b6">6</xref>). The most common adverse effects include urinary tract infections (vulvitis, vulvovaginitis, balanitis and balanoposthitis). Genital infections can be prevented by appropriate genital hygiene. Higher rates of urinary tract infections were not documented (<xref ref-type="bibr" rid="en-b6">6</xref>). Increased genital infection rates were attributed to increased amounts of glucose in urine, which encourage fungal and bacterial growth (<xref ref-type="bibr" rid="en-b1">1</xref>). SGLT-2 inhibitors induce osmotic diuresis with the resulting relative hypovolaemia, which may lead to orthostatic hypotension, reported in less than 3 % of patients. Using SGLT-2 inhibitors as an add-on to diuretics increases the risk for its onset (<xref ref-type="bibr" rid="en-b1">1</xref>,<xref ref-type="bibr" rid="en-b6">6</xref>). Therefore, drinking an extra amount of at least 500 mL of unsweetened fluid is recommended to prevent dehydration during the course of therapy (<xref ref-type="bibr" rid="en-b3">3</xref>). SGLT-2 inhibitors tend to increase LDL cholesterol (by up to 10 %), a finding documented in all patients (average increase – 0.9 mmol/L) (<xref ref-type="bibr" rid="en-b3">3</xref>). Minimal reduction of bone tissue formation, as well as an increase in bone resorption markers were reported, but there were no significant changes in mineral bone density (<xref ref-type="bibr" rid="en-b6">6</xref>). However, the CANVAS trial reported a 23 % increase in the rate of low-energy fractures, especially those involving the upper arm and ribs (<xref ref-type="bibr" rid="en-b17">17</xref>), which was attributed to a small increase in serum phosphate levels. It was found that reduced sodium reabsorption in the proximal renal tubule leads to increased reabsorption of sodium and phosphate through another transporter expressed in the proximal tubule. The net effect of elevated serum phosphate is enhanced parathormone activity and increased bone tissue resorption. Reduction of vitamin D production and calcium absorption occur for the same reason and lead to a decrease in bone mineral density (<xref ref-type="bibr" rid="en-b20">20</xref>). Canagliflozin has been shown to cause a minimal increase in serum potassium levels as well, especially in patients with impaired renal function and subjects who had been treated with drugs exerting effects on potassium levels, such as renin-angiotensin-aldosterone system inhibitors. This phenomenon was not documented in patients treated with empagliflozin or dapagliflozin. The net increase in serum potassium levels is the result of opposing mechanisms, the predominant effects being those responsible for potassium retention (<xref ref-type="bibr" rid="en-b20">20</xref>).</p>
            <p>Patients treated with canagliflozin in the CANVAS trial showed twice the risk for lower limb amputation compared to the placebo group. A higher rate of amputations was documented in men and in subjects with previous amputation, neuropathy or peripheral artery disease. The risk for amputation was not dose-related. The exact cause is yet unknown, but it is supposed to be related to increased haemoconcentration due to osmotic diuresis and hypovolaemia (<xref ref-type="bibr" rid="en-b17">17</xref>,<xref ref-type="bibr" rid="en-b19">19</xref>).</p>
            <p>Treatment with SGLT-2 inhibitors was also reported to cause diabetic ketoacidosis. The majority of affected individuals were patients with type 1 diabetes who received the drug off-label. There were several patients with type 2 diabetes in whom ketoacidosis was triggered by a variety of factors, including acute disease, infection, reduced food and fluid intake, missed insulin dose, surgical procedure or alcohol consumption. In some patients glucose levels were lower than usually noted in diabetic ketoacidosis; in some of them glucose levels were even within the normal range. Potential mechanisms underlying the development of ketoacidosis in patients receiving SGLT-2 inhibitors include: increased glucagon-insulin ratio, enhanced production of free fatty acids, shift from oxidative carbohydrate metabolism to oxidative free fatty acid metabolism, and reduced excretion of ketone bodies (<xref ref-type="bibr" rid="en-b1">1</xref>,<xref ref-type="bibr" rid="en-b22">22</xref>). SGLT-2 inhibitors should be discontinued prior to any major surgery or other invasive procedure associated with potential bleeding risk in order to prevent the development of diabetic ketoacidosis. Preparation for some interventions, e.g.colonoscopy, may cause dehydration. Also, SGLT-2 inhibitor therapy should be discontinued in patients anticipating severe stressful physical activity (e.g.running a marathon). It is recommended to discontinue the medication at least three days before the planned activity, i.e. at least five half-lives of the drug (<xref ref-type="bibr" rid="en-b23">23</xref>). In acute situations, such as vomiting, urgent surgery, or shock, SGLT-2 inhibitors should be discontinued immediately (<xref ref-type="bibr" rid="en-b24">24</xref>). However, no recommendations are available for minor investigations, especially contrast studies. Discontinuation of the treatment is suggested for patients undergoing contrast studies which may cause acute kidney injury with the resulting acidosis. Previous studies have shown that ketoacidosis due to treatment with SGLT-2 inhibitors is preventable because it could be anticipated and recognisable. Routine measurements of ketone levels in urine, however, are not recommended (<xref ref-type="bibr" rid="en-b1">1</xref>,<xref ref-type="bibr" rid="en-b22">22</xref>,<xref ref-type="bibr" rid="en-b24">24</xref>).</p>
            <p>Patients treated with SGLT-2 inhibitors may be at higher risk of developing breast and bladder cancer. No definitive conclusions have yet been reached because of small cohorts and because it was not clear whether the disease was present before the treatment began. Nevertheless, treatment with SGLT-2 inhibitors is not advised for patients with bladder cancer (at present or in the past) (<xref ref-type="bibr" rid="en-b1">1</xref>).</p>
         </sec>
         <sec id="en-s7" sec-type="Availability of SGLT-2 inhibitors in Slovenia">
            <label>7</label>
            <title>Availability of SGLT-2 inhibitors in Slovenia</title>
            <p>Currently, two agents from this group, i.e. empagliflozin and dapagliflozin, are available in Slovenia.</p>
            <p>Empagliflozin is a selective SGLT-2 inhibitor. It exhibits rapid absorption and reaches peak plasma levels one to two hours after administration (<xref ref-type="bibr" rid="en-b25">25</xref>). Its half-life in plasma is 10.3–18.8 hours. The recommended dose of empagliflozin is 10–25 mg once daily. Current guidelines recommend that in patients with impaired renal function the dosage of empagliflizin should be adjusted as follows: with GFR &lt; 60 mL/min the maximum daily dose is 10 mg, while with GFR &lt; 45 mL/min empagliflizin is contraindicated or should be discontinued. With GFR &lt; 60 mL/min, the therapy should not be restarted. In hepatic impairment, dose adjustments are not required, yet data on this subject are scarce (<xref ref-type="bibr" rid="en-b6">6</xref>,<xref ref-type="bibr" rid="en-b25">25</xref>). In Slovenia, empagliflozin, marketed as Jardiance, is also available in combination with metformin, under the brand name Synjardy.</p>
            <p>Dapagliflozin shows greater selectivity for SGLT-2 than for SGLT-1. It exhibits rapid absorption and reaches peak plasma levels one to two hours after administration. Its bioavailability is 78 %. Dapagliflozin metabolism occurs predominantly in the liver and kidney via uridine diphosphate-glucuronosyltransferase (UGT1A9). The recommended dose is 5–10 mg once daily. In hepatic impairment the dose should be reduced from 10 mg to 5 mg daily. According to current guidelines, dapagliflozin is contraindicated in patients with GFR &lt; 60 ml/min (<xref ref-type="bibr" rid="en-b6">6</xref>,<xref ref-type="bibr" rid="en-b25">25</xref>). In Slovenia dapagliflozin is marketed as Forxiga; in combination with metformin it is available under the brand name Xigduo. Results from recent studies suggest that GFR-related restrictions will be relaxed or even removed.</p>
         </sec>
         <sec id="en-s8" sec-type="SGLT-2 inhibitor usage restrictions in Slovenia">
            <label>8</label>
            <title>SGLT-2 inhibitor usage restrictions in Slovenia</title>
            <p>Based on the world literature data SGLT-2 inhibitors can be prescribed as monotherapy or in combination with other glucose-lowering drugs, such as metformin, sulfonylureas, dipeptidyl peptidase 4 (DPP-4) inhibitors or insulin (<xref ref-type="bibr" rid="en-b3">3</xref>).</p>
            <p>According to the guidelines on the use of SGLT-2 inhibitors in the treatment of type 2 diabetes issued by the Health Insurance Agency of the Republic of Slovenia, they can be prescribed only in the folowing cases:</p>
            <list>
               <list-item>
                  <label>1.</label>
                  <p>in combination with metformin or sulfonylurea/repaglinide, when the use of sulfonylurea/repaglinide or metformin is contraindicated, or when adverse effects occured;</p>
               </list-item>
               <list-item>
                  <label>2.</label>
                  <p>in triple therapy with optimal doses of metformin or sulfonylurea/repaglinide, when the doctor or the patient have reservations about insulin treatment;</p>
               </list-item>
               <list-item>
                  <label>3.</label>
                  <p>in combination with insulin and metformin (or without metformin when it is contraindicated or adverse effects occur).</p>
               </list-item>
            </list>
            <p>The drug can be prescribed only on the basis of the report and recommendation provided by a specialist diabetes clinic (<xref ref-type="bibr" rid="en-b26">26</xref>).</p>
         </sec>
         <sec id="en-s9" sec-type="Potential for future use">
            <label>9</label>
            <title>Potential for future use</title>
            <p>The reported beneficial effects of SGLT-2 inhibitors go far beyond glycaemic control and open up new possibilities for their wider use. Diabetes is a disease associated with high cardiovascular risks. Therefore, not only good glycaemic control, but also appropriate protection against cardiovascular events, is of vital importance to diabetic patients. SGLT-2 inhibitors provide both benefits. Moreover, positive effects are exerted also in diabetic patients with a history of past cardiovascular events. Even more, renoprotective effects of SGLT-2 inhibitors are particularly welcome in early-stages of diabetic nephropathy. Additionally, very important is their weigth-loss effect, considering that the majority of patients with type 2 diabetes are overweight. Therefore, ideal candidates for treatment with SGLT-2 inhibitors would be overweight diabetic patients with high cardiovascular risk and early-stage diabetic renal disease. In view of the beneficial effects, one would expect SGLT-2 inhibitors to be more widely used and should be prescribed as a second line treatment (after metformin), yet their wider use seems to be limited by high cost. Another reason for their not being prescribed more frequently is that they have been available for clinical use only for a past few years, so more studies are needed to investigate their long-term effects.</p>
         </sec>
         <sec id="en-s10" sec-type="Conclusion">
            <label>10</label>
            <title>Conclusion</title>
            <p>SGLT-2 inhibitors are a novel group of antihyperglycaemic drugs. Previous studies have confirmed their effectiveness on glycaemic control and also additional beneficial metabolic effects, particularly those associated with weight loss. Additional advantage of SGLT-2 inhibitors is that they decrease blood glucose levels independent of the secretion and action of insulin and therefore do not increase risks for hyperglycaemia. Empagliflozin and canagliflozin have been shown to provide protection against cardiovascular events and the associated complications. After only a few years of clinical use, SGLT-2 inhibitors have proved to be very promising antidiabetic agents, yet further investigations are required to assess possible additional effects on metabolism and potential adverse long-term treatment effects.</p>
         </sec>
      </body>
      <back>
         <ref-list>
            <ref id="en-b1">
               <label>1. </label>
               <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                        <surname>Vallianou</surname>
                        <given-names>NG</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Geladari</surname>
                        <given-names>E</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Kazazis</surname>
                        <given-names>CE</given-names>
                     </name>
                    </person-group>. 
                    <article-title>SGLT-2 inhibitors: their pleiotropic properties</article-title>. 
                    <source>Diabetes Metab Syndr</source>. 
                    <year>2017</year>
                    <month>Oct - Dec</month>;
                    <volume>11</volume>(
                    <issue>4</issue>):
                    <fpage>311</fpage>–
                    <lpage>5</lpage>. 
                    <pub-id pub-id-type="doi">10.1016/j.dsx.2016.12.003</pub-id>
                    <pub-id pub-id-type="pmid">28011230</pub-id>
                    <issn>1871-4021</issn>
                </mixed-citation>
            </ref>
            <ref id="en-b2">
               <label>2. </label>
               <mixed-citation publication-type="webpage">
                    <person-group person-group-type="author">
                        <name name-style="western">
                        <surname>Diabetes Atlas</surname>
                        <given-names>ID</given-names>
                     </name>
                    </person-group>.
                    <source>IDF Diabetes Atlas</source>. 
                    <edition>8th edition 2017</edition>.
                    [<date-in-citation content-type="access-date" iso-8601-date="2017-03-22">cited 2017 Mar 22</date-in-citation>]. 
                    <comment>Available from:<uri>http://www.diabetesatlas.org/#</uri>
                  </comment>.
                </mixed-citation>
            </ref>
            <ref id="en-b3">
               <label>3. </label>
               <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                        <surname>Storgaard</surname>
                        <given-names>H</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Gluud</surname>
                        <given-names>LL</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Bennett</surname>
                        <given-names>C</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Grøndahl</surname>
                        <given-names>MF</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Christensen</surname>
                        <given-names>MB</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Knop</surname>
                        <given-names>FK</given-names>
                     </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Benefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis</article-title>. 
                    <source>PLoS One</source>. 
                    <year>2016</year>
                    <month>Nov</month>;
                    <volume>11</volume>( 
                    <issue>11</issue>):
                    <fpage>e0166125</fpage>. 
                    <pub-id pub-id-type="doi">10.1371/journal.pone.0166125</pub-id>
                    <pub-id pub-id-type="pmid">27835680</pub-id>
                    <issn>1932-6203</issn>
                </mixed-citation>
            </ref>
            <ref id="en-b4">
               <label>4. </label>
               <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                        <surname>Ivo-Dos-Santos</surname>
                        <given-names>J</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Campos</surname>
                        <given-names>DL</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Galvão-Castro</surname>
                        <given-names>B</given-names>
                     </name>
                    </person-group>. 
                    <article-title>Patterns of serologic response to human immunodeficiency virus type 1 (HIV-1) in Brazilians with different clinical forms of HIV infection</article-title>. 
                    <source>Mem Inst Oswaldo Cruz</source>. 
                    <year>1989</year>
                    <month>Jan-Mar</month>;
                    <volume>84</volume>(
                    <issue>1</issue>):
                    <fpage>9</fpage>–
                    <lpage>11</lpage>. 
                    <pub-id pub-id-type="doi">10.1590/S0074-02761989000100003</pub-id>
                    <pub-id pub-id-type="pmid">2319954</pub-id>
                    <issn>0074-0276</issn>
                </mixed-citation>
            </ref>
            <ref id="en-b5">
               <label>5. </label>
               <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                        <surname>Kalra</surname>
                        <given-names>S</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Singh</surname>
                        <given-names>V</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Nagrale</surname>
                        <given-names>D</given-names>
                     </name>
                    </person-group>. 
                    <article-title>Sodium-Glucose Cotransporter-2 Inhibition and the Glomerulus: A Review</article-title>. 
                    <source>Adv Ther</source>. 
                    <year>2016</year>
                    <month>Sep</month>;
                    <volume>33</volume>(
                    <issue>9</issue>):
                    <fpage>1502</fpage>–
                    <lpage>18</lpage>. 
                    <pub-id pub-id-type="doi">10.1007/s12325-016-0379-5</pub-id>
                    <pub-id pub-id-type="pmid">27423646</pub-id>
                    <issn>0741-238X</issn>
                </mixed-citation>
            </ref>
            <ref id="en-b6">
               <label>6. </label>
               <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                        <surname>Kalra</surname>
                        <given-names>S</given-names>
                     </name>
                    </person-group>. 
                    <article-title>Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors: A Review of Their Basic and Clinical Pharmacology</article-title>. 
                    <source>Diabetes Ther</source>. 
                    <year>2014</year>
                    <month>Dec</month>;
                    <volume>5</volume>(
                    <issue>2</issue>):
                    <fpage>355</fpage>–
                    <lpage>66</lpage>. 
                    <pub-id pub-id-type="doi">10.1007/s13300-014-0089-4</pub-id>
                    <pub-id pub-id-type="pmid">25424969</pub-id>
                    <issn>1869-6953</issn>
                </mixed-citation>
            </ref>
            <ref id="en-b7">
               <label>7. </label>
               <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                        <surname>Lioudaki</surname>
                        <given-names>E</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Androulakis</surname>
                        <given-names>ES</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Whyte</surname>
                        <given-names>M</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Stylianou</surname>
                        <given-names>KG</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Daphnis</surname>
                        <given-names>EK</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Ganotakis</surname>
                        <given-names>ES</given-names>
                     </name>
                    </person-group>. 
                    <article-title>The Effect of Sodium-Glucose Co-transporter-2 (SGLT-2) Inhibitors on Cardiometabolic Profile; Beyond the Hypoglycaemic Action</article-title>. 
                    <source>Cardiovasc Drugs Ther</source>. 
                    <year>2017</year>
                    <month>Apr</month>;
                    <volume>31</volume>(
                    <issue>2</issue>):
                    <fpage>215</fpage>–
                    <lpage>25</lpage>. 
                    <pub-id pub-id-type="doi">10.1007/s10557-017-6724-3</pub-id>
                    <pub-id pub-id-type="pmid">28444472</pub-id>
                    <issn>0920-3206</issn>
                </mixed-citation>
            </ref>
            <ref id="en-b8">
               <label>8. </label>
               <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                        <surname>Martens</surname>
                        <given-names>P</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Mathieu</surname>
                        <given-names>C</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Verbrugge</surname>
                        <given-names>FH</given-names>
                     </name>
                    </person-group>. 
                    <article-title>Promise of SGLT2 Inhibitors in Heart Failure: diabetes and Beyond</article-title>. 
                    <source>Curr Treat Options Cardiovasc Med</source>. 
                    <year>2017</year>
                    <month>Mar</month>;
                    <volume>19</volume>(
                    <issue>3</issue>):
                    <fpage>23</fpage>. 
                    <pub-id pub-id-type="doi">10.1007/s11936-017-0522-x</pub-id>
                    <pub-id pub-id-type="pmid">28299616</pub-id>
                    <issn>1092-8464</issn>
                </mixed-citation>
            </ref>
            <ref id="en-b9">
               <label>9. </label>
               <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                        <surname>Zinman</surname>
                        <given-names>B</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Lachin</surname>
                        <given-names>JM</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Inzucchi</surname>
                        <given-names>SE</given-names>
                     </name>
                    </person-group>. 
                    <article-title>Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes</article-title>. 
                    <source>N Engl J Med</source>. 
                    <year>2016</year>
                    <month>Mar</month>;
                    <volume>374</volume>(
                    <issue>11</issue>):
                    <fpage>1094</fpage>.
                    <pub-id pub-id-type="pmid">26981940</pub-id>
                    <issn>1533-4406</issn>
                </mixed-citation>
            </ref>
            <ref id="en-b10">
               <label>10. </label>
               <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                        <surname>Farahani</surname>
                        <given-names>P</given-names>
                     </name>
                    </person-group>. 
                    <article-title>Non-severe Hypoglycemia Risk Difference between Sulfonylurea and Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2-I) as an Add-On to Metformin in Randomized Controlled Trials</article-title>. 
                    <source>J Popul Ther Clin Pharmacol</source>. 
                    <year>2017</year>
                    <month>May</month>;
                    <volume>24</volume>(
                    <issue>2</issue>):
                    <fpage>e32</fpage>–
                    <lpage>40</lpage>. 
                    <pub-id pub-id-type="doi">10.22374/1710-6222.24.2.6</pub-id>
                    <pub-id pub-id-type="pmid">28594482</pub-id>
                    <issn>1710-6222</issn>
                </mixed-citation>
            </ref>
            <ref id="en-b11">
               <label>11. </label>
               <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                        <surname>Cai</surname>
                        <given-names>X</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Yang</surname>
                        <given-names>W</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Gao</surname>
                        <given-names>X</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Chen</surname>
                        <given-names>Y</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Zhou</surname>
                        <given-names>L</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Zhang</surname>
                        <given-names>S</given-names>
                     </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>The Association Between the Dosage of SGLT2 Inhibitor and Weight Reduction in Type 2 Diabetes Patients: A Meta-Analysis</article-title>. 
                    <source>Obesity (Silver Spring)</source>. 
                    <year>2018</year>
                    <month>Jan</month>;
                    <volume>26</volume>(
                    <issue>1</issue>):
                    <fpage>70</fpage>–
                    <lpage>80</lpage>. 
                    <pub-id pub-id-type="doi">10.1002/oby.22066</pub-id>
                    <pub-id pub-id-type="pmid">29165885</pub-id>
                    <issn>1930-7381</issn>
                </mixed-citation>
            </ref>
            <ref id="en-b12">
               <label>12. </label>
               <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                        <surname>Ahmadieh</surname>
                        <given-names>H</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Azar</surname>
                        <given-names>S</given-names>
                     </name>
                    </person-group>. 
                    <article-title>Effects of Sodium Glucose Cotransporter-2 Inhibitors on Serum Uric Acid in Type 2 Diabetes Mellitus</article-title>. 
                    <source>Diabetes Technol Ther</source>. 
                    <year>2017</year>
                    <month>Sep</month>;
                    <volume>19</volume>(
                    <issue>9</issue>):
                    <fpage>507</fpage>–
                    <lpage>12</lpage>. 
                    <pub-id pub-id-type="doi">10.1089/dia.2017.0070</pub-id>
                    <pub-id pub-id-type="pmid">28749169</pub-id>
                    <issn>1520-9156</issn>
                </mixed-citation>
            </ref>
            <ref id="en-b13">
               <label>13. </label>
               <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                        <surname>Shyangdan</surname>
                        <given-names>DS</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Uthman</surname>
                        <given-names>OA</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Waugh</surname>
                        <given-names>N</given-names>
                     </name>
                    </person-group>. 
                    <article-title>SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: a systematic review and network meta-analysis</article-title>. 
                    <source>BMJ Open</source>. 
                    <year>2016</year>
                    <month>Feb</month>;
                    <volume>6</volume>(
                    <issue>2</issue>):
                    <fpage>e009417</fpage>. 
                    <pub-id pub-id-type="doi">10.1136/bmjopen-2015-009417</pub-id>
                    <pub-id pub-id-type="pmid">26911584</pub-id>
                    <issn>2044-6055</issn>
                </mixed-citation>
            </ref>
            <ref id="en-b14">
               <label>14. </label>
               <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                        <surname>Cherney</surname>
                        <given-names>DZ</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Perkins</surname>
                        <given-names>BA</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Soleymanlou</surname>
                        <given-names>N</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Har</surname>
                        <given-names>R</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Fagan</surname>
                        <given-names>N</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Johansen</surname>
                        <given-names>OE</given-names>
                     </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus</article-title>. 
                    <source>Cardiovasc Diabetol</source>. 
                    <year>2014</year>
                    <month>Jan</month>;
                    <volume>13</volume>(
                    <issue>1</issue>):
                    <fpage>28</fpage>. 
                    <pub-id pub-id-type="doi">10.1186/1475-2840-13-28</pub-id>
                    <pub-id pub-id-type="pmid">24475922</pub-id>
                    <issn>1475-2840</issn>
                </mixed-citation>
            </ref>
            <ref id="en-b15">
               <label>15. </label>
               <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                        <surname>Fioretto</surname>
                        <given-names>P</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Zambon</surname>
                        <given-names>A</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Rossato</surname>
                        <given-names>M</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Busetto</surname>
                        <given-names>L</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Vettor</surname>
                        <given-names>R</given-names>
                     </name>
                    </person-group>. 
                    <article-title>SGLT2 Inhibitors and the Diabetic Kidney</article-title>. 
                    <source>Diabetes Care</source>. 
                    <year>2016</year>
                    <month>Aug</month>;
                    <volume>39</volume>
                    <supplement>Suppl 2</supplement>:
                    <fpage>S165</fpage>–
                    <lpage>71</lpage>. 
                    <pub-id pub-id-type="doi">10.2337/dcS15-3006</pub-id>
                    <pub-id pub-id-type="pmid">27440829</pub-id>
                    <issn>0149-5992</issn>
                </mixed-citation>
            </ref>
            <ref id="en-b16">
               <label>16. </label>
               <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                        <surname>Perrone-Filardi</surname>
                        <given-names>P</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Avogaro</surname>
                        <given-names>A</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Bonora</surname>
                        <given-names>E</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Colivicchi</surname>
                        <given-names>F</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Fioretto</surname>
                        <given-names>P</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Maggioni</surname>
                        <given-names>AP</given-names>
                     </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Mechanisms linking empagliflozin to cardiovascular and renal protection</article-title>. 
                    <source>Int J Cardiol</source>. 
                    <year>2017</year>
                    <month>Aug</month>;
                    <volume>241</volume>:
                    <fpage>450</fpage>–
                    <lpage>6</lpage>. 
                    <pub-id pub-id-type="doi">10.1016/j.ijcard.2017.03.089</pub-id>
                    <pub-id pub-id-type="pmid">28395981</pub-id>
                    <issn>0167-5273</issn>
                </mixed-citation>
            </ref>
            <ref id="en-b17">
               <label>17. </label>
               <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                        <surname>Rastogi</surname>
                        <given-names>A</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Bhansali</surname>
                        <given-names>A</given-names>
                     </name>
                    </person-group>. 
                    <article-title>SGLT2 Inhibitors Through the Windows of EMPA-REG and CANVAS Trials: A Review</article-title>. 
                    <source>Diabetes Ther</source>. 
                    <year>2017</year>
                    <month>Dec</month>;
                    <volume>8</volume>(
                    <issue>6</issue>):
                    <fpage>1245</fpage>–
                    <lpage>51</lpage>. 
                    <pub-id pub-id-type="doi">10.1007/s13300-017-0320-1</pub-id>
                    <pub-id pub-id-type="pmid">29076040</pub-id>
                    <issn>1869-6953</issn>
                </mixed-citation>
            </ref>
            <ref id="en-b18">
               <label>18. </label>
               <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                        <surname>Zinman</surname>
                        <given-names>B</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Wanner</surname>
                        <given-names>C</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Lachin</surname>
                        <given-names>JM</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Fitchett</surname>
                        <given-names>D</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Bluhmki</surname>
                        <given-names>E</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Hantel</surname>
                        <given-names>S</given-names>
                     </name>, 
                        <etal>et al</etal>; 
                        <collab>EMPA-REG OUTCOME Investigators</collab>
                    </person-group>. 
                    <article-title>Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes</article-title>. 
                    <source>N Engl J Med</source>. 
                    <year>2015</year>
                    <month>Nov</month>;
                    <volume>373</volume>(
                    <issue>22</issue>):
                    <fpage>2117</fpage>–
                    <lpage>28</lpage>. 
                    <pub-id pub-id-type="doi">10.1056/NEJMoa1504720</pub-id>
                    <pub-id pub-id-type="pmid">26378978</pub-id>
                    <issn>0028-4793</issn>
                </mixed-citation>
            </ref>
            <ref id="en-b19">
               <label>19. </label>
               <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                        <surname>Neal</surname>
                        <given-names>B</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Perkovic</surname>
                        <given-names>V</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Mahaffey</surname>
                        <given-names>KW</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>de Zeeuw</surname>
                        <given-names>D</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Fulcher</surname>
                        <given-names>G</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Erondu</surname>
                        <given-names>N</given-names>
                     </name>, 
                        <etal>et al</etal>; 
                        <collab>CANVAS Program Collaborative Group</collab>
                    </person-group>. 
                    <article-title>Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes</article-title>. 
                    <source>N Engl J Med</source>. 
                    <year>2017</year>
                    <month>Aug</month>;
                    <volume>377</volume>(
                    <issue>7</issue>):
                    <fpage>644</fpage>–
                    <lpage>57</lpage>. 
                    <pub-id pub-id-type="doi">10.1056/NEJMoa1611925</pub-id>
                    <pub-id pub-id-type="pmid">28605608</pub-id>
                    <issn>0028-4793</issn>
                </mixed-citation>
            </ref>
            <ref id="en-b20">
               <label>20. </label>
               <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                        <surname>Filippatos</surname>
                        <given-names>TD</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Tsimihodimos</surname>
                        <given-names>V</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Liamis</surname>
                        <given-names>G</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Elisaf</surname>
                        <given-names>MS</given-names>
                     </name>
                    </person-group>. 
                    <article-title>SGLT2 inhibitors-induced electrolyte abnormalities: an analysis of the associated mechanisms</article-title>. 
                    <source>Diabetes Metab Syndr</source>. 
                    <year>2018</year>
                    <month>Jan - Mar</month>;
                    <volume>12</volume>(
                    <issue>1</issue>):
                    <fpage>59</fpage>–
                    <lpage>63</lpage>. 
                    <pub-id pub-id-type="doi">10.1016/j.dsx.2017.08.003</pub-id>
                    <pub-id pub-id-type="pmid">28826578</pub-id>
                    <issn>1871-4021</issn>
                </mixed-citation>
            </ref>
            <ref id="en-b21">
               <label>21. </label>
               <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                        <surname>Lytvyn</surname>
                        <given-names>Y</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Bjornstad</surname>
                        <given-names>P</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Udell</surname>
                        <given-names>JA</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Lovshin</surname>
                        <given-names>JA</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Cherney</surname>
                        <given-names>DZ</given-names>
                     </name>
                    </person-group>. 
                    <article-title>Sodium Glucose Cotransporter-2 Inhibition in Heart Failure: Potential Mechanisms, Clinical Applications, and Summary of Clinical Trials</article-title>. 
                    <source>Circulation</source>. 
                    <year>2017</year>
                    <month>Oct</month>;
                    <volume>136</volume>(
                    <issue>17</issue>):
                    <fpage>1643</fpage>–
                    <lpage>58</lpage>. 
                    <pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.117.030012</pub-id>
                    <pub-id pub-id-type="pmid">29061576</pub-id>
                    <issn>0009-7322</issn>
                </mixed-citation>
            </ref>
            <ref id="en-b22">
               <label>22. </label>
               <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                        <surname>Rosenstock</surname>
                        <given-names>J</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Ferrannini</surname>
                        <given-names>E</given-names>
                     </name>
                    </person-group>. 
                    <article-title>Euglycemic Diabetic Ketoacidosis: A Predictable, Detectable, and Preventable Safety Concern With SGLT2 Inhibitors</article-title>. 
                    <source>Diabetes Care</source>. 
                    <year>2015</year>
                    <month>Sep</month>;
                    <volume>38</volume>(
                    <issue>9</issue>):
                    <fpage>1638</fpage>–
                    <lpage>42</lpage>. 
                    <pub-id pub-id-type="doi">10.2337/dc15-1380</pub-id>
                    <pub-id pub-id-type="pmid">26294774</pub-id>
                    <issn>0149-5992</issn>
                </mixed-citation>
            </ref>
            <ref id="en-b23">
               <label>23. </label>
               <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                        <surname>Goldenberg</surname>
                        <given-names>RM</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Berard</surname>
                        <given-names>LD</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Cheng</surname>
                        <given-names>AY</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Gilbert</surname>
                        <given-names>JD</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Verma</surname>
                        <given-names>S</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Woo</surname>
                        <given-names>VC</given-names>
                     </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>SGLT2 Inhibitor-associated Diabetic Ketoacidosis: Clinical Review and Recommendations for Prevention and Diagnosis</article-title>. 
                    <source>Clin Ther</source>. 
                    <year>2016</year>;
                    <month>Dec</month>;
                    <volume>38</volume>(
                    <issue>12</issue>):
                    <fpage>2654</fpage>–
                    <lpage>64</lpage>. 
                    <pub-id pub-id-type="doi">10.1016/j.clinthera.2016.11.002</pub-id>
                    <pub-id pub-id-type="pmid">28003053</pub-id>
                    <issn>0149-2918</issn>
                </mixed-citation>
            </ref>
            <ref id="en-b24">
               <label>24. </label>
               <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                        <surname>Handelsman</surname>
                        <given-names>Y</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Henry</surname>
                        <given-names>RR</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Bloomgarden</surname>
                        <given-names>ZT</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Dagogo-Jack</surname>
                        <given-names>S</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>DeFronzo</surname>
                        <given-names>RA</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Einhorn</surname>
                        <given-names>D</given-names>
                     </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>American Association of Clinical Endocrinologists and American College of Endocrinology Position Statement on the Association of Sglt-2 Inhibitors and Diabetic Ketoacidosis</article-title>. 
                    <source>Endocr Pract</source>. 
                    <year>2016</year>
                    <month>Jun</month>;
                    <volume>22</volume>(
                    <issue>6</issue>):
                    <fpage>753</fpage>–
                    <lpage>62</lpage>. 
                    <pub-id pub-id-type="doi">10.4158/EP161292.PS</pub-id>
                    <pub-id pub-id-type="pmid">27082665</pub-id>
                    <issn>1530-891X</issn>
                </mixed-citation>
            </ref>
            <ref id="en-b25">
               <label>25. </label>
               <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                        <surname>Scheen</surname>
                        <given-names>AJ</given-names>
                     </name>
                    </person-group>. 
                    <article-title>Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus</article-title>. 
                    <source>Drugs</source>. 
                    <year>2015</year>
                    <month>Jan</month>;
                    <volume>75</volume>(
                    <issue>1</issue>):
                    <fpage>33</fpage>–
                    <lpage>59</lpage>. 
                    <pub-id pub-id-type="doi">10.1007/s40265-014-0337-y</pub-id>
                    <pub-id pub-id-type="pmid">25488697</pub-id>
                    <issn>0012-6667</issn>
                </mixed-citation>
            </ref>
            <ref id="en-b26">
               <label>26. </label>
               <mixed-citation publication-type="book">
                    <person-group person-group-type="editor">
                        <name name-style="western">
                        <surname>Zaletel</surname>
                        <given-names>J</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Ravnik Oblak</surname>
                        <given-names>M</given-names>
                     </name>, 
                        <role>eds</role>
                    </person-group>. 
                    <source>Slovenske smernice za klinično obravnavo sladkorne bolezni tipa 2</source>. 
                    <edition>3th ed</edition>. 
                    <publisher-loc>Ljubljana</publisher-loc>:
                    <publisher-name>Klinični oddelek za endokrinologijo, diabetes in presnovne bolezni; Interna klinika UKC Ljubljana in Klinični oddelek za endokrinologijo, diabetes in bolezni presnove; Pediatrična klinika Ljubljana</publisher-name>;
                    <year>2016</year>.
                </mixed-citation>
            </ref>
         </ref-list>
      </back>
   </sub-article>
</article>
